1220 Artificial Intelligence Companies - Worldwide

199 Biotechnologies is an early-stage
company developing first-in-class therapies that target the fundamental mechanisms of aging, with the goal of transforming the landscape of age-related disease treatment and prevention.

At 1STBIO, we strive to transform the lives of patients by relentlessly discovering and developing novel therapeutics to address areas of significant unmet need. Inspired by science and innovation, we dedicate our expertise and experience in drug development to bring forward a pioneering change.

20/20 GeneSystems (‘20/20’) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. Our headquarters are in the heart of the biotechnology corridor in Rockville, Maryland in close proximity to the National Institutes of Health with which we have extensive collaborations. 20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. This technology is now being used to develop tests to predict responses to several new targeted therapies for kidney and lung cancer. Early detection of lung cancer: 20/20 is developing a blood test for the early detection of lung cancer. This product will be used for screening smokers and former smokers to pre-select or enrich the patient population to receive annual CT scanning long before the disease becomes symptomatic. Biological Detection: 20/20 is on the leading edge of developing technologies to help in the detection of biological toxins.

3billion is revolutionizing the existing methods and procedures to enable more people to benefit from faster and much accurate diagnosis at an affordable cost. [Who is 3billion?] - 3billion provides an AI-driven clinical diagnostic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases for patients and physicians in need. - 3billion reanalyzes the undiagnosed patients’ genomic data every day without any additional charge. About 10% of undiagnosed patients can receive diagnosis by reanalysis. - More than 40,000 rare diseases patients from more than 60 countries have been tested. - More than 93% of acceptance rate on the 3billion’s test report by physicians. - 3billion has been collaborating with 100 medical institutions across 33 countries to make a diagnosis for rare disease patients. [Core Technology Features] - 3billion has expertise in medical genetics. We have streamlined the analysis pipeline using an automated variant prioritization system and are currently leading diagnostic technology by developing a pathogenicity prediction model of human variants. - 3billion devised a variant interpretation system, EVIDENCE, to automate the process. With the help of EVIDENCE, the variant interpretation takes less than 5 minutes per patient on average. - The EVIDENCE produces consistent variant interpretation according to the current medical guideline, ACMG-AMP interpretation guideline. 3billion's medical geneticist gives the diagnosis and confirms reported variants by Sanger validation (Richards S et al, 2015). - The analysis reflects the latest updates on diseases and genetic variants on daily basis. If any diagnosed case is identified through reanalysis, 3billion provides a report without any additional charge. - We offer Whole Exome Sequencing (WES) & Whole Genome Sequencing (WGS) for rare disease diagnosis. - Web-based portal service – easy access from all over the world. For any inquires, please contact us at support@3billion.io

3CPM Corporation is a Medical Technology company that offers a non-invasive 45-minute test using AI-derived patented technology to accurately characterize gastrointestinal motility disorders such as gastroparesis and functional dyspepsia.

3Z uses advanced disease modeling and behavioral genetics to discover novel drug candidates for CNS disorders.

About 4D Lifetec AG 4D Lifetec is a pioneer on a mission to revolutionize early cancer detection. Our easy and powerful blood tests can detect cancer at its earliest stages (I and II), offering you peace of mind and proactive well-being protection. Sophisticated artificial intelligence (AI) enhances our immunological high-throughput blood assays which in turn enables timely intervention and treatment.

Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible.

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point of need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in bioprocessing, pharma/biopharma, forensics, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

Ability Biologics is dedicated to developing innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The company utilizes its powerful AbiLeap™ discovery engine, which combines massively parallel, continuously learning AI with advanced cell targeting technology, to develop the most potent and selective antibody therapeutics for areas of great unmet need.

Abiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins with powerful, desirable pharmacological properties, redefining what therapeutics can achieve for patients across a range of disease areas. Abiologics was founded by Flagship Pioneering in 2021.

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

Founded in November 2020, AccuPulse is dedicated to become a globally leading innovator in cardiac electrophysiology industry. The core team members come from companies such as J&J, GE, Acutus Medical and Abbott with in-depth experience in R&D, registration and commercialization of cardiac electrophysiological medical devices. The company has built R&D centers in both China and the United States, and the company is backed by top scientists, physicians and famous venture capital firms.

Overview: AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to building strong partnerships, and collaborates across academia and the pharmaceutical industry to solve interdisciplinary problems. The company was founded in 2015 and has locations in both Shanghai, China and New York, NY. Products & Services: Accutar offers two software packages: Chemi-Net and Orbital. Chemi-Net is a molecular graph convolutional network for accurate drug property prediction. It was recently shown to improve the accuracy of ADME property prediction by a large margin in comparison to the widely-used methods https://arxiv.org/abs/1803.06236. Orbital is a deep neural network based docking platform. The prediction accuracy of protein-ligand complex (holo) from ligand free state (apo) structure is significantly higher than current standards. In addition to these tools, AccutarBio offers services in virtual screening for lead discovery; intelligent-SAR for lead optimization and drug property prediction.

AcelaBio, wholly owned by The Alimentiv Health Trust, was incorporated in 2020 and aims to meet the growing clinical research demand for quality and efficiency in laboratory service. Our state-of-the-art facility, located in San Diego, California, is built on deep expertise in clinical and precision medicine research and our scientific and operational experts are dedicated to delivering reliable, high-quality data.

Our mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. To fulfill our vision, we work with our customers by becoming key technology partners, boosting their discovery workflow with the most innovative solutions. Science, research, innovation, and development are the founding pillars of our company.

Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson's, diabetes and cancer. Acelot's platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelot's first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer's. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Achira is building atomistic foundation simulation models to power the future of drug discovery.

Acorai is developing a device for heart failure management through non-invasive cardiac and pulmonary pressure sensing, to help reduce hospitalizations and readmissions. Our product can monitor cardiac and pulmonary pressure sensing non-invasively through a machine-learning analysis of pressure dynamics in acoustics, vibratory, and waveform data. Our technology shows compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement, and a fast track to commercialization.

AcroViz develops novel imaging biomarkers for brain health, in an effort to prolong human health span with state-of-art technologies. Comprising eminent academia researchers and experienced industrial professionals, the team is devoted to advancing scientific research, maximizing its clinical significance and application, as well as commercialization to achieve extended positive impact. The first product: AcroViz Axonal Brain Age – Brain Health Report, is the first to the market that adopting diffusion Magnetic Resonance Imaging (dMRI) and Machine Learning techniques to provide accurate and objective brain health assessment, which can serve as a Mild Cognitive Impairment (MCI) marker in predicting the risk and prognosis of dementia, such as Alzheimer's Disease (AD). Web acroviz.com/en/ FB www.facebook.com/acroviz IG www.instagram.com/acroviz_brainhealth YT www.youtube.com/@acroviz LINE https://lin.ee/T2Ttyyj

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Actnova is a South Korean startup specializing in AI SaaS solutions. The company platform automates the behavioral testing process in clinical and non-clinical fields with artificial intelligence image processing technology. Actnova is also a manufacturer of materials inspection, measurement, and analysis instruments.

AcuraStem (acurastem.com) is a near-to-clinic, patient-based, drug development company pioneering drug discovery and ultimately how treatments are developed for neurodegenerative diseases—including sporadic ALS and FTD. Enabled by our ground-breaking iNeuroRx® technology platform - AcuraStem has discovered and is now advancing drug candidates that promise to strongly impact disease progression for most patients, including those for whom the genetic cause of their disease is unknown (i.e. sporadic ALS and FTD patients). The causes of neurodegenerative diseases are complex, and genetically defined forms of disease (e.g. C9ORF72-ALS and FTD) only account for a small percentage of cases. Thus, many scientists didn’t believe it was possible to develop a single effective treatment that could work broadly for all patients. But AcuraStem has shown with its extremely promising therapeutic programs for ALS and FTD that it can be done.

Adaptive Clinical Systems, a global life sciences technology company, offers a simple, secure, validated, compliant and cost-effective solution for data interoperability as well as reporting and visualization for clinical trials. Adaptive Clinical offers the Adaptive eClinical Bus and Adaptive DataVIEW. The Adaptive eClinical Bus®, a cloud-based hosted service, will integrate with any EDC, eCOA, CTMS, ePRO/IWRS, Medical Imaging, IRT, Analytics, Data Acquisition Systems as well as RWD, EHR/EMR to reduce error and speed data management for any size study. With the Adaptive eClinical Bus, patient- centric clinical trials can ensure interoperability and full compliance from the many diverse eSources generated from the explosion of data from Digital Health Technologies (DHTs), such as wearables and remote patient monitoring (RPM) solutions. Key benefits of the Adaptive eClinical Bus include: ✔️ Fully-validated Platform with Detailed Audit Logs and Reports ✔️ Fully compliant with HHS 45 CFR Part 64, FDA 21 CFR Part 11, GxP and other regulatory guidelines ✔️ Standards-based for Interoperability ✔️ Easily Implement an eSource Data Capture Workflow ✔️ Adaptive Rules Engine offers Built-in Clinical Intelligence ✔️ Reusable components for Quick Installation ✔️ Full training and 24/7 support Adaptive DataVIEW provides a robust solution for visualizing and analyzing data from disparate sources quickly and efficiently. It provides real-time, bi-directional data from many disparate sources into comprehensive dashboards. Purpose built for clinical trial operational key performance indicators and dashboards. Reports can be created at the patient, site, study or program level, including across studies. Adaptive DataVIEW enables "single click-back" from any widget or dashlet to the data source regardless of eClinical tool.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

Develops a rapid leukocyte differential instrument is used to screen for infections, allergies, and blood-related cancers including leukemia.

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We're committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.

We are committed to the growth and development of companies and organizations using advanced therapeutic technologies to revolutionize medicine through specialized, bespoke advisory services. At Adjuvant Partners, we leverage our expertise, professional network, and pan-industry perspectives to provide unique, tailored solutions to our clients to best suit their needs. We believe in active participation with stakeholders throughout the industry, and in concert with our clientele work to foster continued growth, expansion, and implementation of advanced therapies across the healthcare spectrum.

Admetsys is a biomedical technology company specializing in critical care automation. The company's flagship PrecisionOne system is the first fully automated glycemic control system and continuous blood diagnostics platform for hospital care. The company was founded to commercialize the next generation of medical automation technology: continuous real-time biosensing, robotics, artificial intelligence and learning algorithms, intelligent therapeutic delivery, and advanced data telemetry.

AeroFarmsis an indoor vertical farming company. They usea patented aeroponic growing system to grow produce.

Aether's mission is to build a future of abundance for the human race. We believe that the machinery of nature can be reverse engineered to manufacture any arrangement of atoms desired, enabling the production of new products anywhere on earth.

Afecta Pharmaceuticals is an early clinical stage small molecule therapeutics company focused on developing precision medicines to treat chronic disorders and cancers more effectively. Afecta has a validated, proprietary Artificial Intelligence disease/drug targeting platform, PharmetRx®, to discover and optimize Multi-Target drug compounds and formulate them in NanoRx®, our tissue-specific drug delivery technology. Backed by an experienced management team, Afecta is currently advancing AFX-220, our clinically proven lead candidate that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD, and others. Please visit our website to learn more, register to access our Executive Summary, and receive our latest updates.

Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world.

AgBiomeis usingknowledge of the crop microbiome and an extensive network of field-sampling partners to build a proprietary microbial strain collection that is both diverse and large—larger, in fact, than the major public strain collections. Unlike many programs, which only use metagenomics surveys, the AgBiome platform is focused on true isolated microbial strains, which provideinsight into the genomic composition of crop-associated microbes. The company uses this collection as a resource for discovering new biologicals and trait genes.Existing microbial classification systems based on 16S rDNA sequences or other fingerprinting technologies are imprecise—microbes that are classified as ‘the same’ often differ by hundreds of genes. AgBiome uses proprietary algorithms based on whole genome sequence to classify organisms in their collection. This allows the company to measure the true diversity of plant-associated microbes at the gene level—and genes determine function and performance. The company has also applied our whole-genome methods to their straincollection.

AgeCurve Limited is a company that offers tools to measure scalable single cell somatic mutation burden across the life sciences market space. They also provide a deep age profiling kit intended to calculate comprehensive biological aging patterns in a saliva sample.

Aging is the main cause behind most illnesses that eventually kill us. Your chance of dying doubles every 8 years. By the time you turn 80, half of your peers are dead. However, it turns out aging is a biological process, amenable to treatment. Research has demonstrated that we can postpone the onset of age-related disease. Lab mice know this already. Experiments with caloric restriction, senolytics and metabolic inhibitors have extended life and reversed aging - in mice. But how do we know these treatments will work in humans? We can wait and see if patients receiving these new treatments die later. Or see if onset of age-related disease is postponed. But this is slow. It takes many, many years to know for sure if the treatments work. Wouldn’t it be great if we had a faster way? Thanks to the discovery of the epigenetic clock, we can now accurately describe changes to gene regulation caused by aging. By turning this discovery into a blood test, we can measure the exact aging status inside human cells. This will be incredibly useful to researchers involved in aging research. They would know if a treatment works, much earlier than before. So that’s what we’re making: A biomarker for aging which is accurate, affordable and quick.

Agilis Robotics is a spin-off company from The University of Hong Kong that develops flexible robotic instruments for endoscopic surgery. We aim to provide clinicians with enhanced robotic dexterity and precision while leveraging current clinical workflows.

a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement. The technology has been pioneered by the company’s co-founders Madeline Lancaster and Juergen Knoblich and is exclusively licensed to a:head by the Institute of Molecular Biotechnology, Vienna, Austria. a:head applies these complex 3D tissue cultures for modelling of various brain disorders in a human context and aims at translating the technology into a powerful high content, high throughput phenotyping platform for the development of novel CNS therapeutics.

We help entrepreneurs form new teams and build AI-first startups. Apply on our website for $500k investment, up to $1M in free AI compute, and network of AI founders and researchers. We bring together world-class engineers, researchers, and entrepreneurs to create new companies together from scratch. From ideation to execution, we help generate ideas, find co-founders, secure pilot customers, integrate cutting-edge AI, and more. Our hands-on support guides founders through building, scaling, and raising millions in venture funding. In 6 years, we've backed 40+ companies now valued at $1B+, raising $220M+ and creating 700+ jobs. Our startups are transforming industries: improving immigrant communication (Yoodli), accelerating cancer research (Ozette and Modulus), enhancing legal efficiency (Lexion, acquired by DocuSign), turning smartphones into medical devices (PreemptiveAI), and so much more. Any VC can write a check, but what truly sets us apart is our unparalleled technical and AI expertise. With our heritage at the Allen Institute for AI—founded by Microsoft co-founder Paul Allen—we’ve been singularly focused on commercializing AI long before it became a buzzword. AI2 has 200+ PhDs, researchers, engineers, professors, and support staff—and is well known for its contributions to the A.I. research community including 600+ papers, 20+ best paper awards, and numerous products/open-source offerings including SemanticScholar, AllenNLP, and more. Our core team includes pioneers like Oren Etzioni, a leader in AI for over three decades, and our deep technical expertise means we don’t just back you financially—we help you build breakthrough products, navigate complex challenges, and accelerate your company’s growth. We're soon launching AI House in Seattle, a central hub for AI innovation. In partnership with the Mayor of Seattle and supported by Washington state, this space will serve as a central hub for the region’s AI community.

A.I. Analysis, Inc. is a medical software company specializing in the application of artificial intelligence (AI) to radiology. A.I. Analysis, Inc.’s first product is the Change Detector for Brain Imaging, a machine-learning based system that compares serial MR imaging studies and presents changes in the form of a color overlay superimposed on the anatomical images. The Change Detector saves radiologists time at the beginning of their reading — perhaps up to 10 minutes for diseases such multiple sclerosis. The Change Detector highlights the locations of changes and degree of those changes, so the radiologist can more quickly reach clinical judgments. Using the Change Detector, it may be possible for radiologists to detect changes months earlier than is possible with manual inspection alone, with greater reproducibility.

Aiberry is an AI-powered multimodal platform that offers providers and care managers rapid, objective, and unbiased behavioral health assessments. Aiberry delivers evidence-based insights virtually (in telehealth scenarios) and at the point of care, offering unique outreach and scale opportunities.

-Artificial Intelligence powered Drug Discovery. -a Biopharma company specialized in medicinal chemistry research of preclinical drug candidates. Ai-biopharma has in-silico solutions of Chemoinformatics, Molecular Modeling, Docking, Data analysis, SAR formatting/interpretation and also an Artificial Intelligence platform for the accelerated drug design towards the selection of new preclinical candidate drugs .

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis, across a variety of fields from oncology to neuroscience and more. From empowering researchers in the identification of novel biomarkers of disease, and supporting R&D scientists in speeding up time-to-market of novel drugs, to helping pathologists enhance the accuracy of cancer diagnostics — Aiforia has the expertise and experience to transform healthcare all the way from discovery to diagnosis.

Aigen is accelerating the transition to regenerative agriculture. We're launching the world's first AI-driven, network connected robotic fleet, powered entirely by the elements. Aigen is building a future with no harmful chemicals in our food. Backed by NEA, GFC, AgFunder, Regen.vc, and Bessemer Ventures

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase. Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity. AIGEN Sciences will revolutionize AI-based drug discovery.

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

AILIS is a pioneering technology. It combines Dynamic Parametric Imaging, artificial intelligence, and telemedicine to immediately detect symptoms of breast cancer and estimate the risk of developing the illness. Our mission is to provide women with dense breasts with access to efficient and comfortable testing based on imaging that detects early symptoms of breast cancer, and to guarantee them with comprehensive care in terms of monitoring their health. Technologies that change the world are always a result of long and hard work of a team of non-accidental people. At AILIS, everyone has a purpose. We are a team of experts and specialists in a number of fields and we share common values. At AILIS, we share common values and principles that we follow in everyday work. To protect the health of millions of women in an honest, responsible, and respectful way. Never to lose our passion for science. And to develop a technology that is authentic in terms of its mission, as well as a service that will become a synonym for protectiveness.

Ainnocence is a next-generation biotech company with a fast, self-evolving AI drug design platform. The company's third-generation AI system delivers lightning-fast virtual screening and multi-objective pharmacological profile optimization for small-molecule, antibody, and other complex therapeutic modalities. This platform provides a computational screening capacity of up to 10^10 protein sequences or chemical compounds within hours. The end results are a shortlist of candidates with a very high wet-lab hit rate, and a dramatically reduced discovery time and cost. To learn more, visit ainnocence.com.

Ainos Inc. is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, women's health, pneumonia, Ainos Pen, AI Nose, and other medical technologies. The company was founded in 1984 and is engaged in developing innovative medical technologies for point-of-care testing and safe and effective treatments for various health conditions.

Aiosyn is a Dutch healthtech company that is developing precision pathology software solutions for breast cancer and chronic kidney disease. Aiosyn launched its first automated QC test on the EU market (AiosynQC) and the first clinical diagnostic test for breast cancer is pending regulatory approval in the EU. With our NephroPath platform we support CROs and Biopharma with quantifying kidney biomarkers thereby accelerating (pre-)clinical drug development studies.

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.

aitiologic is an Austrian precision medicine startup developing ai-powered solutions for early disease detection and targeted therapy.

We are creating a new category of medicines with the application of spatial biology and AI.

Improve yield, reduce deviations, and ensure product quality in GxP pharmaceutical manufacturing with real-time, practical Artificial Intelligence (AI)- powered software as a service solutions.

Alabama Agricultural and Mechanical University(AAMU) is a historic, student-friendly and community-focused institution of higher learning. Reflecting on its heritage as a historical black college and university (HBCU) and a traditional 1890 land-grant institution, AAMU functions as a teaching, research and public service institution, including extension.

With over 30 years of experience, Alcedis combines medical expertise with ground-breaking technologies to pioneer data-driven clinical research. Our module-based service concept and flexible data capture systems adapt seamlessly to any project structure and accompany your entire research process - from Phase I to drug approval and beyond market access into real-world evidence.

Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

At Alex Therapeutics we provide digital health solutions that enable pharmaceutical companies to better support their products, and their patients. Leveraging our proven modular technology platform allows partners to reduce time-to-market and enables frictionless deployment of safe, secure and effective digital health products. Over 100,000 patients have used our products globally, with our best-in-class user experience design ensuring better health engagement and outcomes.

Algorithmic Biologic's vision is to create a bountiful and healthy world by bringing scale efficiencies to molecular discovery and diagnostics. Our transdisciplinary team has a deep modeling-based understanding of the chemistry and mechanics of molecular technologies. Our first product, Tapestry, is award-winning, regulatory approved algorithmic solution to provide affordable large-scale COVID-19 testing.

Building a modern operating system for IVF, powered by artificial intelligence.

Aliri is committed to solving industry challenges by bringing innovative bioanalysis and spatial solutions to biotech and pharma, as the complexity of the drug development landscape continues to rise. Our mission is to support our customers with bringing life-saving therapies to market with speed and agility. We are focused on providing pharma and biotech companies with bioanalysis lab, spatial bioanalysis, and spatial biology solutions that will bring unique, comprehensive data to enable strategic decision making for lead optimization and strengthen regulatory submissions.

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third-party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving ISO 27001 Certification, SOC 2 Type 2 Certification and HIPAA compliance attestation. AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.

Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases. As a fully-integrated, global biopharmaceutical company, Alkermes applies its scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

Alli Connect is a mental health care service for first responders that proactively promotes wellness and positive change in public safety.

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna’s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through innovation. ATEC’s Organic Innovation Machine™ is the greatest concentration of spine knowhow in the industry and committed to the creation of clinical distinction. Leveraging 100% spine focus and expertise, we seek to improve spine surgery by rethinking, redesigning and seamlessly integrating the technologies required from the ground up. The innovation that results from that process is being rapidly adopted because, like us, spine surgeons covet informatic and procedural sophistication that enables more predictable, more reproducible care. Our flagship technology, the Prone TransPsoas (PTPTM) Procedure, leveraged decades of experience to advance first-generation lateral surgery with a more familiar patient position and elevated neuromonitoring.   EOS imaging, the backbone of ATEC’s informatic ecosystem, provides radiographic imaging, enabling standing, full-body, global alignment assessments. We are further developing EOS technology to elevate spine care with unprecedented capabilities. Our vision is to be the standard bearer in spine. Visit our website for more information: www.atecspine.com

Technology that leverages customer value. ALPINION's an innovative and recognized ultrasound brand ‘E-CUBE' principles (‘Extreme Clarity', ‘Efficient Workflow', ‘Ergonomic Design') reflect ALPINION's technological philosophy that provides customers with uniform image quality throughout the product lifetime. ALPINION has focused on acoustic engineering and front-end technology since we initiated our ultrasound business. There has traditionally been a strong focus on back-end processing in ultrasound; however, we shifted attention to the front-end with a focus on the signal quality sent to system processors. ALPINION focuses on continuous innovation in acoustic technology. ALPINION has developed a range of transducer array types and applied them to ALPINION's innovative E-CUBE series of ultrasound systems. Based upon proprietary superior acoustic technology, ALPINION continuously strives to expand the medical business from diagnostic ultrasound to therapeutic ultrasound.

Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet. Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR), and artificial intelligence (AI). Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop

Aluna is designed to help you understand your chronic respiratory condition (such as asthma) and allow you to take control of your lung health. Using a combination of machine learning, our spirometer device and mobile app, you can now use the daily measurements to help you understand and manage your asthma.

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

Amai develops novel proteins that answer the needs of consumers and industry. The first application is sweet protein, inspired by nature, and built with biology through a natural fermentation process. With its pro-protein platform, the company creates new breakthroughs which are set to shape the future of proteins.

Focusing on generating innovative biological respondents with a unique mode of action coupled with conditionally activated characteristics, we handle high-value disease targets with huge upside potential, which are otherwise intractable for traditional targeting approaches.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches, addressing limitations associated with the use of a narrow range of protein degrading mechanisms. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

Imagine a world in which devastating disease such as cancer is detected sooner; thus, providing doctors the ability to treat patients earlier with better outcomes. Amplified Sciences is a startup life science diagnostics company focused on accurately detecting and pre-empting the risks of debilitating diseases. The company leverages IP licensed from Purdue University and has developed a platform that can scale to point of care. The lead assay is an ultra-sensitive molecular sensing technology revolutionizing #pancreaticcancer. Enabling early detection of debilitating diseases across oncology and chronic kidney disease.

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Since 2012, the Amplitude team has deployed a venture growth model used to build Canadian companies with world-class management teams and scale companies to breakout potential. This model has been used by the team to create, build, and grow companies, resulting in over $1 billion in company value. Our offices are in Montreal, Toronto, and Vancouver.

AMPLY Discovery is a Belfast-based techbio company that deploys machine learning and synthetic biology to mine vast biological data to discover novel drug and nutraceutical candidates. Their technology digitizes life's diversity, using next-gen sequencing for drug discovery to tackle complex diseases such as cancer, metabolic disease, and infectious diseases through AI (artificial intelligence). They have raised over €1.6 million in grant funding from Innovate UK to develop their drug discovery platform.

AMRA Medical is a health informatics company founded in 2010, originating from Linköping University in Sweden. With a team of over 30 employees and a global presence, AMRA specializes in AI-driven medical imaging and precision medicine, particularly in advanced MRI analytics for body composition assessment. The company has achieved regulatory clearances, including CE-Marked medical device status, and collaborates with major industry players like Pfizer Inc. AMRA offers next-generation phenotyping that utilizes AI to analyze whole-body MRI scans, providing precise fat and muscle biomarkers for personalized health insights. Their cloud-based platform ensures secure, quality-controlled results with a quick turnaround and is compatible with various MRI scanners. The company also develops imaging biomarkers and disease phenotypes through partnerships, aiming to create a global representative database. Under the leadership of CEO Eric Converse and co-founders Magnus Borga and Olof Dahlqvist Leinhard, AMRA focuses on equipping clinicians and researchers with actionable data to manage conditions such as obesity and metabolic disorders.

At Amsterdam UMC, more than 15,000 professionals strive to provide good and accessible care. For the generations of today and tomorrow. The two medical university centers in Amsterdam, AMC and VUmc, are working together towards a future in which we prevent illnesses and make the best treatment available to all patients. To this end, we develop new methods for diagnostics and treatment together with professionals from other renowned national and international institutions. We treat over 350,000 patients a year at both our sites - AMC and VUmc. Our main focus is on complex patient care and highly-specialized treatment of rare medical conditions. At Amsterdam UMC, we teach and train thousands of young people to become doctors, specialists or nurses. Our researchers are clustered in eight research centers so that we can achieve our ambition of executing international, cutting-edge research. At Amsterdam UMC, AMC and VUmc are working together on academic patient care, scientific research and teaching & training.

Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Welcome to Anatomise Biostats. Our biostatistics services are designed to support Biopharma and Medtech/Medical Device SMEs and start-ups in their R&D and clinical trials projects throughout the regulatory approval process and beyond. 💡 Our Mission: We aim to facilitate innovation in the life sciences sector while assuring patient benefit and safety, offering unwavering support throughout your journey. 🌐 Who We Serve: Our services cater exclusively to Biopharma and Medtech/Medical Device SMEs and start-ups, and are fine-tuned to address unique industry challenges as they arise. 📈 Specialized Expertise: Our team of biostatistics and bioinformatics experts ensures data-driven precision in your R&D and clinical trials. 🔍 Navigating Regulatory Waters: We guide you through evolving regulatory requirements with confidence. 🤝 Dedicated Partnership: We're not just consultants; we're committed to the success of your project and longer-term pipeline. 🌟 Results-Focused: Our focus is on delivering accurate insights for informed decision-making. Ready to embark on your life sciences journey? Connect with Anatomise Biostats today, and let's chart a course to success together. #Biostatistics #Bioinformatics #LifeSciences #Medtech #Biopharma #BiometricsConsulting #RegulatoryApproval #ClinicalTrials #FunctionalServiceProvider

AngioInsight, Inc. is a digital health company based in Ann Arbor, Michigan, specializing in artificial intelligence for cardiovascular diagnostics. Founded in 2018, the company develops AI-driven solutions aimed at improving the accuracy and efficiency of diagnosing and managing coronary artery disease (CAD). The AngioAI+ platform is a key offering, designed for real-time assessment during angiography. It provides actionable insights by detecting microvascular dysfunction and quantifying stenosis severity. Additionally, AngioInsight offers fully automated angiogram analysis, which processes coronary angiogram videos to support clinicians in making informed treatment decisions. The company's technology integrates seamlessly into existing clinical workflows, enhancing resource allocation and patient outcomes. AngioInsight has received significant funding, including grants and investments, to support its innovative approach. The company is actively engaged in clinical studies to validate its platform's efficacy, particularly in addressing diagnostic gaps in cardiovascular care. Its solutions are targeted at cardiologists and healthcare institutions that perform millions of angiograms annually.

Anivive is focused on reshaping pet healthcare by bringing together experts in software development, veterinary medicine, and clinical research to accelerate the development of novel therapeutics. Anivive. Smarter for pet health.

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

Anumana™ is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with life-saving treatments. Anumana recently acquired NeuTrace and is leveraging the power of novel ECG-EGM-EMR integration for clinically valuable, actionable insights. With nference's proprietary nSights real-world evidence generation platform, built on data from leading health systems, we combine unparalleled longitudinal structured and unstructured electronic medical record data with diagnostic and interventional ECGs and EGMs. By applying AI techniques to these electrical signals from the heart, the company has uncovered clinically critical electrical signatures and patterns unrecognizable to the human eye. The resulting software products can be integrated into routine clinical practice for earlier disease diagnosis and in-procedure decision-making. Anumana's 75+ peer-reviewed publications and ongoing research show significant promise to detect and diagnose otherwise hidden conditions earlier and uncover actionable insights for valuable patient interventions. The opportunity to offer clinical decision support tools for each unique patient throughout the cardiac care continuum paves the way for precision medicine. Anumana strives to introduce a new standard of care in cardiac clinical care supported by reimbursement.

Are you ready for a transformative leap in small bowel capsule endoscopy? Meet ProScan, our cutting-edge AI Assisted Reading Tool meticulously designed to revolutionize the diagnostic process for patients suspected of small bowel bleeding. ProScan leverages advanced artificial intelligence algorithms to significantly reduce the time required for reviewing capsule endoscopy studies, enabling quicker and more precise diagnoses. It is meticulously engineered to expedite the evaluation of capsule endoscopy images, enhancing the timeliness of a diagnosis and initiation of therapy. Headquartered in Plano, Texas, AnX Robotica brings versatility in development and integration of multi-discipline technologies such as precise magnetic, robotic control, in house ASIC design, artificial intelligence, micro-optical imaging, image processing, and wireless transmission. With more than 200 patents granted or applications pending, and dozens of clinical papers published in major international journals, AnX Robotica, together with its sister companies, have become the leading companies in robotic capsule technology.

Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.

AppHarvest is a sustainable food company in Appalachia developing and operating some of the world’s largest high-tech indoor farms with robotics and artificial intelligence to build a reliable, climate-resilient food system. AppHarvest’s farms are designed to grow produce using sunshine, rainwater and up to 90% less water than open-field growing, all while producing yields up to 30 times that of traditional agriculture and preventing pollution from agricultural runoff. AppHarvest currently operates its 60-acre flagship farm in Morehead, Ky., producing tomatoes, a 15-acre indoor farm for salad greens in Berea, Ky., a 30-acre farm for strawberries and cucumbers in Somerset, Ky., and a 60-acre farm in Richmond, Ky., for tomatoes. The four-farm network consists of 165 acres under glass. AppHarvest is a public benefit corporation and a Certified B Corp.

Applied Surgical Robotics is a MedTech company focused on developing robotic technology and SaaS software solutions to improve surgical precision.

We use next-gen machine learning to find novel psychedelic drug compounds. Classical (first-generation) psychedelics have never been optimized to treat any disease and so we aim to design compounds with the optimal risk-benefit ratio in various indications. Beyond mental health, we focus on neurodegeneration and neural injuries, increasing brain longevity and extending human mental healthspan.

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization. We are growing and hiring! Check our career website: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA on our Welcome To The Jungle page: https://www.welcometothejungle.com/fr/companies/aqemia

Aquavit Pharmaceuticals, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. We focus on personalized medicine to improve patient health and to maximize the efficiency of the medical community. At Aquavit Pharmaceuticals, Inc., we combine this strategic focus with a modern, diverse approach that enables us to pursue new specialty areas with significant unmet needs. Science personalized. Healthcare modernized.

Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development, as well as sharply reducing the enormous cost and time to bring effective treatments to millions of patients. AT leverages over 20 years of international genomics research, pioneering a novel approach to guide its drug development. The company collaborates closely with The Center for Applied Genomics (CAG) at the Children’s Hospital of Philadelphia to repurpose and develop ground-breaking new medical treatments. AT-001, AT's Alzheimer‘s drug candidate, has the potential to become the first cure for dementia, not only treating the disease but preventing it. AT was founded by one of the leading minds in applied genomics, Dr. Hakon Hakonarson, who launched CAG in 2006 and established it as the largest paediatric biobank and genomic database in the world.

Arctoris Ltd is a biotechnology company founded in 2016 and based in Oxford, UK, with additional locations in Singapore, Boston, and Abu Dhabi. It operates as a tech-enabled Partnership Research Organization (PRO) and utilizes its proprietary Ulysses platform, the first fully automated drug discovery platform, to enhance research and development processes for biotech, pharmaceutical, and academic partners. The company employs over 40 experts in various fields, including cellular and molecular biology, biochemistry, and machine learning. Arctoris offers services such as Experiments-as-a-Service, integrated drug discovery, and collaborative R&D, providing end-to-end support from target identification to preclinical candidate development. The Ulysses platform combines robotics and advanced data science to deliver high-quality datasets, reducing human error and accelerating project timelines. Arctoris collaborates with biotech startups, large pharmaceutical companies, and AI-driven drug discovery firms, focusing on oncology, neurology, and other therapeutic areas.

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Ardigen is a bioinformatics company that specializes in AI-driven solutions for drug discovery and precision medicine.

Argon AI is a platform that allows biopharmacy and life sciences experts to conduct complicated, data-driven operations. They help life sciences companies automate their data-intensive workflows with unprecedented AI.

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

AriBio is a clinical-stage biotech company located in Seongnam, South Korea focused on developing novel therapeutics for neurodegenerative diseases. The US office is located in San Diego managing global clinical operations and regulatory affairs. The lead asset, AR1001, is entering a global phase 3 program this year.

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

Arrow Dx is combining Nanotechnology and Artificial Intelligence (AI) to create an inexpensive, sensitive test to screen early for non-alcoholic fatty liver disease (NAFLD). Our aim is to provide physicians with an alternative to liver biopsy which detects the disease too late. We are working to solve the lack of rapid, reliable, point-of-care, and inexpensive diagnostic devices by bring faster, inexpensive and mobile testing for many other applications that require a rapid response (e.g., epidemic/pandemics, public health crisis, early diagnosis for rising complex non-communicable diseases, testing in emergency rooms). Our technology makes it more affordable for smaller healthcare providers such as Physician Office Labs (~100,000 in the U.S.), independent physicians and public health workers to access diagnostics due to our significantly lower cost as well as our portable, small compact size. Finally, we are also working to create a test for COVID-19 as well as other viruses, initially quantifying the virus in wastewater to help public health authorities and later to detect it in biological samples from individuals and patients.

ArsenalBiosciences, Inc., is a privately held, clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.

Artera is a SaaS digital health leader redefining patient communications. Artera is trusted by 700+ healthcare systems and federal agencies to facilitate approximately 2.2 billion messages annually, reaching 100+ million patients. The Artera platform integrates across a healthcare organization’s tech stack, EHRs and third-party vendors to unify, simplify and orchestrate digital communications into the patient’s preferred channel (texting, email, IVR, and webchat), in 109+ languages. The Artera impact: more efficient staff, more profitable organizations and a more harmonious patient experience. Founded in 2015, Artera is based in Santa Barbara, California and has been named a Deloitte Technology Fast 500 company (2021, 2022, 2023), and ranked on the Inc. 5000 list of fastest-growing private companies for four consecutive years. Artera is a two-time Best in KLAS winner in Patient Outreach.

Arterys was founded to facilitate the global advancement of medicine through data, artificial intelligence and technology. Because a significant proportion of the world's medical data resides in medical images, Arterys set out to tackle several issues around the space, including the enormous workloads radiologists face, the lack of accuracy with many of today's tools, and the need for increased consistency across practices. The company was the first to receive FDA clearance for a cloud-based product with Artificial Intelligence, and currently has 8 FDA clearances, and is active in 118 countries. Arterys continues to focus on solving some of radiology's most pressing needs. We deliver the most comprehensive set of clinical AI solutions in the industry, built off a single platform and user interface that focuses on users with seamless workflow integration and a unified and optimized UI for every one of our applications. By making imaging diagnostics quantitative, intelligent and available, we empower healthcare organizations to improve physicians' experience, patient outcomes, efficiency, and reduce costs with cloud and AI. Arterys has offices in San Francisco, Calgary and Paris. For more information, please visit www.arterys.com. Follow Arterys on Twitter at @ArterysInc at https://twitter.com/ArterysInc.

Artificial accelerates the pace of life science discoveries by making connecting and orchestrating labs easy with its cloud-based software platform, the Artificial Product Suite. As a vendor-agnostic platform, the Artificial connects with any native instruments, devices, databases, and informatics to provide a single, easy-to-use orchestration layer for the entire lab. Using Artificial, scientific labs can control and monitor their processes in real-time while capturing AI-ready data and keeping humans in the loop.

Artos helps clinical development and medical writing teams turn their data into regulatory submissions in days instead of weeks. Life sciences companies spend $13 billion and millions of man-hours each year on regulatory submissions for health agencies. At Artos, we build AI and software tools to shrink those timelines so that life-saving treatments can get to patients sooner.

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests. With more than 3,000 employees, ARUP offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays. ARUP is an Equal Opportunity Employer M/F/D/V and supports a drug-free environment. Scammers have been posing as ARUP recruiters to target jobseekers using fraudulent email addresses and social media accounts. ARUP recruiters will only contact you with legitimate offers by calling from 800-522-2787 or 801-583-2787 or emailing from an address ending in @aruplab.com. Read our full fraud statement on aruplab.com/careers

Arxspan provides cloud-based solutions to meet the scientific data management needs of leading life sciences, chemicals, and scientific companies globally. Arxspan offers ArxLab®, a suite of web-based scientific informatics applications, allowing scientists to record, manage, and share their research data​: * Notebook - Intuitive electronic laboratory notebook (ELN) optimized for collaborative models in current research environments * BioReg/ChemReg Registration - Configurable repository for registering unique chemical/biological entities and subsequent batches * Assay - Flexible system for registering assay protocol and result data * Inventory - Comprehensive tool for defining and managing chemical and biological compounds, reagents, equipment, and other items * Search - Robust decision support platform for querying, visualizing, and reporting data * Workflow - ArxLab Workflow allows users to create new work requests and to assign them to users and/or groups. The workflow management tool enables scientists to manage and prioritize all scientific projects, as well as to make procedure requests to internal colleagues and external partners. For more information, please visit our website at www.arxspan.com

Arzeda combines protein design, pathway design, HT screening and strain construction to create and improve designer fermentation strains for virtually any chemical. One example of their work is indeveloping new and improved enzymes to make rare sugars, natural sweeteners,and other oligosaccharides.

Established in 2016, Asa Rén is the 1st DNA data company in Indonesia with the most comprehensive bioinformatics in South East Asia. We aim to enable innovation in Indonesia's healthcare industry through utilization of longitudinal data and genomic data for drug discovery and personalized treatments.

Ascertain, a healthcare technology company empowering care teams with AI, helps health systems, payers, and independent provider groups streamline operations and reduce administrative burden. Customers can either deploy Ascertain Automate, an enterprise software platform that uses agentic AI to automate high-volume administrative workflows, or engage Ascertain's tech-enabled services, outsourcing entire workflows to Ascertain's team, which operates the software on their behalf. From prior authorization and eligibility checks to discharge planning and patient scheduling, Ascertain's AI agents navigate complex systems, interpret unstructured data, and integrate across fragmented platforms — enabling faster throughput, lower costs, and more time for patient care. Ascertain was launched by Northwell Holdings, the for-profit investment arm of Northwell Health, and Aegis Ventures.

Asensus Surgical is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.Senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: https://www.senhance.com/indications.

Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform from cells to software to design and manufacture next-generation therapeutics, including cell & gene therapies, through a combination of products, services, & collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million.

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck℠, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.

Our vision is a world transformed by insect technology. Our mission is to harness the combined powers of technology and nature to pioneer the future of sustainable farming. We are creating tomorrow's traditions through breakthrough innovations that are in harmony with our largest stakeholder: our planet. We believe in technology that unleashes, rather than replaces, the incredible treasures of our natural world. We Aspire to a world that is abundant in planet-based nutrition that is better for people, pets and plants. Every company's culture is defined by its people and their actions. Who we are is the direct product of what we do and what we value. At Aspire, our culture is defined by the following attributes which spell the name of our company: • Audacity (we are competitive, innovative, and dream big) • Skill (we are competent, data-driven, and curious) • Passion (we are impact-centered, profit-minded, and market-driven) • Integrity (we are ethical, trusting, humble and candid) • Resilience (we face adversity and setbacks with fierce determination and collaboration) • Excellence (we aim to be world class in everything we do and believe generosity is a competitive advantage)

Develops a software solution, NICUtrition™, to improve thecare of preterm infants by providing quantitative data about gut health, allowing for personalized care and nutrition to optimize growth and outcomes.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

At Asterra Labs, we are pharmaceutical scientists and industry veterans with a passion to innovate, develop, and manufacture a pharmaceutical-grade line of safe, beneficial wellness products and alternative medicines.

Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.

Atgenomix is a data and machine learning (ML) company that provides an open standard and unified platform for operationalizing biomedical data, analytics, and ML to deliver on the promise of precision medicine. The Atgenomix cloud-based biomedical informatics platform empowers clinical laboratories to design, develop, and operate GA4GH (Global Alliance for Genomics & Health) standard orchestrated multimodal workflows of data integration, tool engineering, analysis automation, workload acceleration, and regulatory compliance management. At Atgenomix, we envision a technology that will transform healthcare in routine clinical genomics and artificial intelligence. We aim to provide industry accessible computational lab technologies that researchers need to scale data and machine learning in the future. Atgenomix is a Microsoft Azure cloud partner in gold data and cloud platform competencies, and a Google Health trusted partner in genomics research.

At Athelas we're bringing simple, life-changing health care products and medical billing services to patients and providers around the globe. Athelas Revenue Cycle Management (RCM): Billing and reimbursement don't have to be painful. Athelas RCM delivers world-class service, maximizes reimbursements, and delivers actionable insights into the financial health of your practice. Athelas prides itself on end-to-end revenue cycle management. This means we cover all aspects of RCM besides simple submission - include denials, working A/R, research, and more as the backbone of your healthcare business. Athelas has powered revenue intelligence for hundreds of healthcare businesses, from small clinics to large health systems. Athelas Remote Patient Monitoring (RPM): We allow healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for Inflammatory Bowel Diseases, lupus, and cancer. The company is focused on developing precision therapeutics for novel & specific subtypes of patients.

Atom Bioworks is a startup company that specializes in DNA nanostructures.

Developed a proprietary platform that holds the potential to discover novel structure targets across the transcriptome and for the design of RNA-targeted small molecules, RNA-based medicines and RNA tools.

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers

ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.

Augere Medical is a commercial stage Norwegian medical device company founded in 2018 and is developing systems based on Artificial Intelligence (AI) to improve polyp detection rates during screening for colorectal cancer. The term "augere" is derived from Latin, meaning "to increase" or "to grow" - hence the green color in our logo. It is the root of several words in English and other languages, including "authority," which signifies the power to promote or bring about growth. Augere’s first product, the PolypAID System, is being developed in cooperation with leading colonoscopists and in close cooperation with the research group at Simula. The PolypAID System analyses the real-time video stream during colonoscopy screening and supports the physicians in making the right decision during the screening process. We pledge to implement transparent AI to physicians and patients. These are our values, mission, vision, and tagline statements: OUR VALUES Quality We are delivering high quality products through focus on details and by meeting customer expectations.   Innovation We are in the forefront of the technology development by embracing continuous improvements and investing in our employees.   Care We care about the patients who will benefit from our technologies and put real heart into our promises to our investors and customers.   Agility We move fast and are willing to adapt to changing market conditions regardless of the size of the company.   Delivering results We have grit to deliver results by defining clear objectives and by meeting deadlines. MISSION Making lives better   VISION Augere will, through partnerships with the world's leading clinical and technical research environments, develop a platform for AI-based systems that improve the detection rate and characterization of cancer and precancerous abnormalities and thereby reduce the burden on patients and the cost of cancer treatment   TAGLINE Confidence in outcomes (TM)

Augmenta Bioworks discovers new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity. Our technology pinpoints the protective immune response of individuals and translates discoveries into therapies.

Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.

Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

Auxilium Health is developing low-cost and smart biomaterials for hard-to-heal wounds. Our mission is to empower patients to take control of their healing journey by providing technology that actively heals and monitors wound infections, enabling faster recovery times and better quality of life for patients. We are providing a smarter way to heal wounds, one patient at a time.

Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit.

Avicenna Biosciences was founded to solve the intractable challenges that previously stopped drug candidates in their tracks. We have created an ML-driven medicinal chemistry platform that makes Lead Optimization faster, cheaper, and more successful – transforming sub-optimal development candidates into life-saving drugs. The platform has seen rapid success in discovering the first orally available, CNS-penetrant ROCK inhibitors for the treatment of neurodegenerative diseases, with IND-enabling studies initiated just one year since the program kicked off.

Cancer doesn’t wait — so we shouldn’t either. At Avitia, we’re making sure that clinical labs and oncologists everywhere have the tools they need to diagnose, as well as treat cancer faster. Our AI/ML technology ensures partners have cost-effective NGS-based molecular testing solutions that provide rapid turnaround times. Now, we empower healthcare teams to skip the delays and focus on what matters — personalized patient care. From pinpointing cancer mutations to streamlining clinical trial access, we’re here to make precision oncology accessible for every community and improve patients’ quality of life. Let’s transform cancer care together. Le cancer n’attend pas, et nous ne devrions pas non plus attendre. Chez Avitia, nous veillons à ce que les laboratoires cliniques et les oncologues du monde entier disposent des outils dont ils ont besoin pour diagnostiquer et traiter le cancer plus rapidement. Notre technologie IA/ML garantit à nos partenaires des solutions de tests moléculaires NGS rentables qui offrent des délais d’exécution rapides. Désormais, nous permettons aux équipes de soins de santé d’éviter les retards et de se concentrer sur ce qui compte : des soins personnalisés aux patients. De l’identification des mutations cancéreuses à la rationalisation de l’accès aux essais cliniques, nous sommes là pour rendre l’oncologie de précision accessible à toutes les communautés et améliorer la qualité de vie des patients. Transformons ensemble les soins contre le cancer.

Axcelead Drug Discovery Partners, Inc. will combine scientific excellence, world-class IP protection and state-of-the art GLP accredited facilities and capabilities to deliver integrated end-to-end early discovery.

Axiom helps scientists eliminate molecular toxicity by providing the most accurate and affordable predictive models. Our proprietary dataset includes more than 100,000 molecules tested in pooled primary human liver cells, tens of thousands of molecules with pharmacokinetic measurements, and thousands of molecules with curated clinical outcome data. Axiom's AI models offer higher accuracy than advanced in vitro systems like 3d spheroids, deep mechanistic understanding which untangles mitochondrial toxicity, ER stress, ROS formation, cytotoxicity, and more, and precise risk assessment for any molecule at relevant clinical dosage and clinical exposure levels. Our models remove the need for costly physical experiments, giving more accurate and cheaper toxicity assessments, and empowering scientists to make better-informed decisions and bring safer drugs to the clinic.

AxoSim empowers advancements in human neuroscience by partnering with biopharma companies to facilitate breakthroughs in devastating neurological diseases and disorders. Their proprietary drug discovery platforms NerveSim®, BrainSim®, and microBrain™ deliver clinically-relevant data to select better lead candidates with phenotypically accurate assays. AxoSim's platforms have applications in peripheral neuropathy and neuropathic pain, disease modeling (such as ALS, MS, and CMT), and neurotoxicology.

Symphony Ayasdi is a FinTech company that specializes in AI-driven machine learning and data analytics solutions for financial services.

Bactobio is a London-based biotechnology company that uses synthetic biology, next-generation sequencing, and machine learning to culture the 99% of microbes which have previously been unculturable. Our exclusive access to nature's greatest bioresource allows us to discover novel chemical and biological products in both healthcare and agriculture. Our first targets are to discover novel antibiotics against the worst bacterial infections and help make plant protection sustainable.

BAMF Health is the world's first vertically integrated platform for molecular imaging and radiopharmaceutical therapy. Using the most advanced imaging and therapy technologies, BAMF Health is dedicated to providing comprehensive and intelligent treatment options for patients with serious health issues such as cancer, heart disease, and stroke.

Basecamp Research is a market leader in mapping biodiversity for AI-based design of biological systems. We match and refine novel proteins for our partners' exact industrial, therapeutic or diagnostic applications using BaseGraph™, a new generation of AI design that is powered by the first-ever high-resolution map of global genetic biodiversity. Understanding the full genetic, evolutionary, and environmental context of each protein allows Basecamp Research to design tailored proteins for specific applications without the need for expensive and time-consuming directed evolution campaigns. We're a team of explorers, scientists and policy experts driven by our ambition to protect and learn from nature's diversity, whilst delivering life-changing breakthroughs to those who need them most.

Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field.

BCAL Diagnostics is an Australian-owned, ASX listed, biotechnology company. Since its establishment in 2010, BCAL Diagnostics has been striving to help identify health issues in women that is safe, accessible and cost effective.

Purpose-built for organizations conducting clinical trials and observational studies, we leverage our AI-powered patient-matching platform and clinical expertise to optimize feasibility and speed up patient identification by extracting structured and unstructured data from electronic medical records (EMRs) that captures three times more trial criteria. Why: We believe sites are vital to the success of clinical trials. Empowering them to find the right patient for the right research at the right time is the focus of everything we do. What: We leverage our best-in-class technology and data expertise to detect more protocol-eligible candidates than traditional methods, so that site teams can focus on the parts of the job they actually love. How: We deliver an AI-powered software platform and support from clinical experts that enables our customers to find and match patients to available clinical research. With unbelievably fast and highly-accurate data extraction from electronic medical records (EMRs) we can capture three times more trial criteria - making trial participation more accessible and efficient.

BenchSci is a biotechnology company that offers an AI-powered platform to accelerate biomedical research by providing researchers with antibody search and selection tools.

BERGis aclinical-stage,AI-powered biotechnology company taking a bold ‘Back to Biology™, approach to healthcare. By leveraging a proprietary intelligence platform – Interrogative Biology®, their goal is to map disease and develop new treatments for patients.COVID-19: Testing their technology in reducing COVID-19 patient mortality.

BERTIS Inc.'s proteomics technology provides diagnostic services that detect cancer and various diseases in the early stages. Proteomics is a field that studies the roles of various proteins, their relationships, and their characteristics, and that can research proteins directly involved in disease occurrence and progression, using technology simultaneously analyze hundreds of proteins as accurate and exquisite. About 10 years ago, when there was no interest in proteomics in Korea, BERTIS Inc. pursued proteomics scientific research after seeing the global scaled potential. As a result, We have secured unique technology based on 25 million protein big data and A. I. and have grown into a leading proteomics company in Korea. And now, we are working hard to go beyond the Republic of Korea into a global representative proteomics company. We constantly communicate and endeavor with experts representing each field, including physicians, chemists, biologists, and engineers.

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They are focused on moving Prenatal Screening and Liquid Biopsy forward to improve disease detection.

BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses >65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge’s preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.

At BioAI, we are developing world-leading machine learning technology to map the causal biology of disease, develop digital biomarkers, and identify novel drug targets, for the development of better medicine. BioAI’s PredictX Platform intakes your data and generates novel insights. PredictX is capable of ingesting a range of data types including: Digital Pathology, Multiomics, and Real-World Evidence. Using multimodal data and the most advanced AI methodologies, including In-silico phenotype projection and integrated deep learning, we can build predictive and prognostic models across a broad range of therapeutic areas. Founded by a group of friends who started by scribbling their ideas on a piece of paper, today we offer smart, innovative services to dozens of clients worldwide. Our team of experts has a proven track record in developing strategic partnerships with the Pharma industry and solving major challenges in R&D

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.

We are commercializing a revolutionary new class of fieldable aerosol mass spectrometers and complementary products for protection from biological and low-volatility chemical threats.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.

BioGeometry is an AI-driven biotech dedicated to developing next-generation, programmable protein medicines. We aim to solve the high cost, long lead time, low success rate problems for traditional macromolecular theraputics through the combination of geometric deep learning, structural biology, immunology, and synthetic biology. We enjoy talents from renowned pharmaceutical companies, top-tier AI and bio labs worldwide.

The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making. Our Solutions We offer a versatile portfolio of proprietary proteomics services, software, and kits. We make these widely available for pharmaceutical and biotechnology researchers and proteomics experts. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all major sample types – cells, tissues, or body fluids – across human and non-human species. Our Technology Biognosys is the leading inventor and developer of mass spectrometry-based proteomics solutions. With market leading proteome coverage and sample throughput we enable simultaneous quantification of thousands of proteins across thousands of samples. Our Facility From our global headquarters just outside of Zurich, we operate one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research. Our Data Competence Biognosys has analyzed a vast amount of proteomics data and developed an industry-leading understanding of the proteome. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. Global Presence Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys today is an established leader in next-generation proteomics. With employees based across Switzerland, Europe, and US, and an extensive network of collaborators and distributors, Biognosys supports a global customer base of life science researchers across industry and academia.

Later part of the bygone twentieth century has witnessed a major revolution in the field of life-sciences. Researches carried out during this period, particularly in the area of molecular biology and recombinant technology, have led to emergence of 'Biotechnology'​ with a new face. Plants, animals and microorganisms being a key component of our ecosystem have always remained at centre-stage of research for different purposes as they affect the human life. Development of culture methods, better understanding about molecular biology, discovery of restriction endonucleases and their use in mapping of DNA laid the foundation stone for modern day biotechnology. Isolation of thermostable DNA polymerase along with the development of PCR technique made cloning simplified and providing way for rec-DNA technology. Further developments were generation of bar-code like DNA fragment patterns of genomic DNA. These patterns appeared useful in distinguishing individuals based on DNA sequence variations among them. Such variations of DNA among organisms were termed as fingerprints or profiles which provide a versatile tool to characterize genetic variability, genome evolution, population genetics, taxonomy, breeding and diagnostics even today! The technology to read the DNA base-by-base made it possible to identify useful genes. This information which could be cloned in suitable vectors and introduced in appropriate hosts through a variety of gene transfer methods gave an impetus to genetic improvement programmes and production of Genetically modified organisms. Today the genomic sequencing is contributing to identify the basis of pathology, providing tailored therapies. We are quickly advancing towards the in situ engineering of the genomic information to achieve designer humanity. Bioheaven ventures into this space "Turning Human Needs into Careful Solutions"​..........

BioLizard is a leading multi-national data analytics and data management consulting company supporting digital transformation in the life sciences industry by offering bespoke, tailored solutions. From data analytics and bioinformatics, to software development and AI, we support biopharma and biotech companies in accessing vital, data-driven insights that can be turned into actions and drive your life sciences research forward. Our team of experienced bioengineers, software engineers and computer science experts combines extensive data science expertise with deep biological knowledge to provide solutions that are tailored to your needs and in line with your unique strategic goals. We have a proven ability to support companies from discovery to pre- & early clinical phases, enabling data-driven R&D. Our expertise spans drug and biomarker discovery and development, in silico screening, target identification, development of companion diagnostics, mechanism-of-action studies, process automation, data strategy, and more. As your true data partner, we’re ready to help you leverage data to keep your competitive edge. Our expert ‘Lizards’ can support you no matter where you are in the world, and in a flexible, proactive, and agile way to drive your data-driven research forward. 𝗥𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝘁𝗼 𝗕𝗶𝗼𝗟𝗶𝘇𝗮𝗿𝗱 𝘁𝗼𝗱𝗮𝘆 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗯𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗮𝘁𝗮 𝗶𝗻𝘁𝗼 𝗮𝗰𝘁𝗶𝗼𝗻𝗮𝗯𝗹𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀. More information: https://lizard.bio/home Company video: https://www.youtube.com/watch?v=q9MR126aiNo&t=1s BioLizard careers: https://lizard.bio/careers

Biolojic Design makes developable, active human antibodies directed against functional epitopes, including targets for which existing technologies fail.

BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create ADCs with improved internalization and trafficking. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML.

BioMap is an AI for life sciences company, unmasking nature’s rules to generate proteins for a wide range of therapeutic and industrial applications. We build super-scale Foundation models supported by access to unrivaled computational power through our strategic collaboration with Baidu, with whom we share our Founder and Chairman, Robin Li. We supplement our AI capabilities with a leading team of scientists, disease experts and cutting-edge high-throughput labs which generate large volumes of high quality proprietary data for our AI models. We partner with pharma, biotechs and industry to enable their discovery ambitions across a wide range of therapeutic and synthetic biology modalities through access to our AI technology platform, with a variety of flexible collaboration models. Our mission is to leverage AI to radically improve lives.

BioMark is an oncology-focused company with advanced near-to- market diagnostic technologies designed to improve patient outcomes. We have developed and own multiple intellectual properties (IPs) in detection and quantitation of metabolites. We hand-picked a proven, global enterprise team of scientists, engineers and medical professionals to help commercialize our innovative technology and to increase prediction and accuracy in the diagnosis of cancers by following and incorporating the highest regulatory ,clinical and scientific standards.. Our cross pollinated, balanced and committed team was established in 2007. Our mission is to develop and commercialize innovative technologies to increase prediction and accuracy in diagnosis of cancers.

Biomeme's platform transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance. The system includes a docking station for real-time PCR, a mobile app to control the system and analyze results, and targeted test kits for preparing samples and identifying pathogens or diseases by their specific DNA or RNA signatures. The cutting edge platform performs to the gold standard used by the world's most advanced central labs but requires no lab equipment or special experience to use. The low-cost, user-friendly system enables mobile testing at the point-of-need for health care (mobile clinics, disease tracking, home use), agriculture (plant disease tracking, food safety), vector surveillance (Malaria, West Nile mosquitos), veterinary medicine, environmental monitoring (soil and water safety), and even education and citizen science.

BiomeSense is a pioneering life sciences startup focused on harnessing the power of the gut microbiome to revolutionize personalized medicine. With our breakthrough technologies GutLab and MetaBiome, we are setting new standards in microbiome data analysis and interpretation, enabling unprecedented insights to understand & leverage the microbiome for human health.

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

Biomonadic is an early stage techbio startup leveraging AI and IoT to resolve critical supply chain bottlenecks affecting the cell and gene therapy (CGT). They are creating a next generation AI empowered data platform for biotech manufacturing, leveraging reinforcement learning and LLMs to augment their capabilities.

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

BioPharm International® covers all aspects of biopharmaceutical development, analysis, processing, and packaging, as well as business strategies and regulatory issues. The print and digital editorial coverage provides technical and business insight and analysis for all biologic-based therapies including monoclonal antibodies, vaccines, biosimilars, protein therapeutics, cell therapies, gene therapies, antibody-drug conjugates, and other emerging therapies.

Providing high-sensitivity quantification services for ultra-trace proteins, we will support research and development of pharmaceuticals, quasi-drugs, reagents, etc.

Bioptimus is a developer of a universal AI foundation model designed to drive advancements in scientific research and biotechnological innovations. Their mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine.

Biology is at a tipping point for implementing AI - thanks to rich data, tool availability, compute capacity, and measurable business impact. Our goal is to empower every scientist and biotech firm, making AI-powered insights a natural part of every workflow. From alt-protein foods to new biopharmaceuticals, bioraptor will make it easier, quicker and more cost-effective for scientists to discover, develop and scale processes that get much-needed food and pharma products into the hands of those who need them.

We provide services in genomics, statistics, and information technology. Our services include Bayesian analysis, bioinformatics, biomarker development, biostatistics, data management, data pipelines, data science, epigenomics, genetics, genome-wide association, imputation, microarray analysis, multiomics, next-generation sequencing analysis, pharmacogenomics, polygenic risk scores, predictive modeling, project management, proteomics, reproducibility, software development, statistical computing, statistical genetics, and statistical programming. We also developed the Smokescreen® Genotyping Array, advancing research into addiction and treatment approaches. Our highly-skilled transdisciplinary team of experts, carefully assembled from leading research universities and industry, has been solving our clients' research challenges for almost two decades. Extensive experience with a wide range of cutting-edge methods and technologies means we can help ensure your project's success, and provide high-quality deliverables on time and within budget. Whether you have a critical issue, need help with every aspect of a new project—including coordinating complex projects—or only one part of an ongoing project, we can work with you to develop the optimal solution to meet your goals and objectives. Our team can be an integral part of the collaboration, and provide full-service support for all the stages of your research journey. We follow all U.S. Department of Health & Human Services standards for the security of electronic protected health information (HIPAA-compliant). We believe in reproducible, reusable, transparent, and extensible research, and do everything we can to put those values into practice. We are prepared to use our internal computing environment, cloud-computing environments, or client-provided environments, if preferred.

At Bioscibex, we are redefining bioprocessing with innovative single-use bioreactor solutions tailored for modern biologics and cell therapy manufacturing. Our mission is to empower researchers and manufacturers with tools that simplify processes, enhance scalability, and improve efficiency.

We help scientists solve disease, develop drugs, and extend healthspan by building tools that simplify R&D, simulate biology, and untangle the complexity of life. Streamline computational analysis today. Discover drugs tomorrow.

Biostate.AI is a startup founded in 2023 with the mission of developing generative AI for predictive omics analytics in the healthcare sector. They offer services such as RNA sequencing, DNA sequencing, image sequencing, image data analysis, and more. The company aims to lower costs and increase the utility of RNA sequencing for research and drug discovery.

BioStrand is a biotechnology company that offers an AI-powered biotherapeutic SaaS platform revolutionizing drug discovery.

BioTherapeutics Inc (BTI) synergistically combines the power of advanced computational modeling, data analytics and artificial intelligence with translational experimentations to accelerate the development of innovative products for precision medicine and health. Our computational platform assembles biomedical and healthcare data from the molecular, cellular, tissue and population levels and leverages the latest innovations in technology to turn those data into answers to complex biological questions and solutions to healthcare's problems.

Biotia is a health tech company launched from Jacobs Technion-Cornell Institute at Cornell Tech in association with Weill Cornell Medicine, located in New York, NY, that leverages DNA sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Biotia is developing a next-generation sequencing-based test for COVID-19 that characterizes genetic variance across the whole viral genome.

BioTuring is an innovative bioinformatics company based in San Diego. Founded in 2016, the company has developed transformational bioinformatics platforms for sequencing data analysis, enabling scientists to gain valuable insights from biological data in an interactive, fast, and accurate approach. Its product portfolio now covers single-cell and spatial data analysis with BBrowserX, Talk2Data, Lens, BioVinci, and BioColab. BioTuring helps accelerate life sciences and nourishes computational minds.

BIOTYPE is an innovative German solution provider for molecular precision diagnostics. We are committed to advancing precision medicine through our products & services for reliable analysis and interpretation of clinical biomarkers. BIOTYPE offers a strong portfolio in molecular cancer diagnostics for applications in hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio includes IVD assays for clinical diagnostics and RUO assays for translational and clinical research. In addition, BIOTYPE offers high-quality and IVD-compliant contract development and manufacturing services. Our proprietary MODAPLEX platform is a benchtop system for automated molecular profiling and multi-biomarker testing. MODAPLEX addresses the growing need to simplify and accelerate precision testing by reliably delivering actionable molecular information required for biomarker-guided care in precision medicine. The MODAPLEX consolidates multi-gene testing into one workflow with same-day results. BIOTYPE‘s quality management system is certified according to ISO 9001:2015 & ISO 13485:2016.

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF, FR:5LB), formerly BioVaxys LLC, is a British Columbia-registered clinical-stage biotechnology company dedicated to improving patient lives with novel immunotherapies based on our DPX™ immune-educating delivery technology platform and our HapTenix© neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase IIb clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© neoantigen tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. BioVaxys is capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.

Biovista is a biotechnology company located in Charlottesville, Virginia, founded in 2005 by CEO Andreas Persidis. The company specializes in AI-driven drug repositioning and development services, aiming to enhance the efficiency of bringing new treatments to market. Biovista offers services that include drug repositioning, which identifies new therapeutic uses for existing drugs, and drug de-risking, which assesses and mitigates potential risks in drug development. The company also conducts disease cohort analysis to better understand specific patient populations and treatment strategies. Biovista develops its own drug repositioning programs across various therapeutic areas, including central nervous system disorders, diabetes and obesity, eye disorders, and oncology. The company employs advanced AI technologies to analyze large datasets, facilitating the discovery of novel applications for existing drugs. Biovista is actively involved in R&D projects, reflecting its commitment to advancing drug discovery through innovative approaches.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.

Birch Biosciences uses Artificial Intelligence, bioinformatics, and high-throughput screening techniques to effectively engineer enzymes for recycling plastic.

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio's trademarks, visit www.bit.bio/trademarks

BostonGene is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer.

It is the mission of the College to engage students of uncommon promise in an intense full-time education of their minds, exploration of their creative faculties, and development of their social and leadership abilities in a four-year course of study and residence that concludes with a baccalaureate degree in the liberal arts.

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.

We turn ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. Impactful. Scalable. Smart. Brainomix 360 enhances stroke imaging interpretation for neurologists, interventionalists, and radiologists while seamlessly fitting into existing radiology workflows. Delivering the right insights, to the right people, at the right time. Since our 2010 spin-out from the University of Oxford, we've developed award-winning, AI-powered imaging biomarkers and software solutions that empower physicians worldwide to make critical, life-saving decisions in stroke and lung care.

For the first time, researchers and companies can accelerate innovation with accessible, accurate, real-time, and reliable Brain Data™ and Brain Insights™.

Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply. Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development. We are currently envisaging clinical collaborations. Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.

Briefly helps give scientists headspace to design their experiments.  Our experiment builder helps create clear, consistent, visual experimental plans, with a copilot that takes care of the busywork.

Brightseed is a pioneer in biosciences and artificial intelligence (A.I.) that illuminates nature to restore human health. Brightseed’s proprietary A.I., Forager®, accelerates bioactive discovery, biological validation and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Through Forager® and clinical evaluation, Brightseed partners with organizations across the consumer health continuum to offer insight into the world of bioactives and health solutions. Brightseed produces branded, proprietary, clinically proven bioactives that are sold to leading dietary supplement, food & beverage CPG, specialty nutrition and medical food companies for incorporation into health beneficial consumer products. Visit www.brightseedbio.com to learn more.

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs

Buck Institute for Research on Aging is a biomedical research institute focused on studying the aging process and its effects on health.

Smart, scalable, and automated insect farming. Bug Mars uses computer vision and machine learning to increase yield and profitability of insect farms for food, feed, and organic waste reduction.

BullFrog AI (NASDAQ: BFRG) is a technology-enabled life science company using advanced artificial intelligence (AI) to usher in the next generation of lifesaving therapies. With our leading-edge platform, bfLEAP™, we aid in accelerating and de-risking drug discovery and clinical development using one of the industry's most advanced graph analytic AI technologies. The Problem: The drug development landscape is littered with failed products and unrealized ROI — all while patients are desperately waiting for treatments that often don't come: • The cost of bringing a drug to market is $.8 to $2.8 billion • Almost 90% of drugs don't get there • The average time to market is 8.5 YEARS Our Solution: We're applying machine learning and AI in drug development to identify new potential therapeutic targets, optimize clinical trials, rescue and repurpose drugs for new indications, and discover new drug targets. By identifying hidden relationships in clinical data, we aim to mitigate risk and elevate the trajectory of precision medicine. Our Technology: The bfLEAP™ platform delivers in a way that neural network models cannot: Explainable AI. We use network models in an interactive graph machine learning format to display and explain your data insights with confidence. Say goodbye to "black box" processing and say hello to AI outputs you can explore and understand. Join Us in Our Mission: With our platform's superior capabilities, a high-powered team of industry experts, and a pipeline of exclusive in-licensed assets for clinical development, BullFrog AI is pushing the boundaries of AI-assisted drug development. Make BullFrog AI an extension of your organization and clear your analytical barriers. Leap into the next generation of drug development with BullFrog AI.

Bullseye Biosciences is a therapeutics discovery company revolutionizing drug development through robotics and evolution. Our platform operationalizes cutting-edge directed evolution technology by incorporating automation and Next Generation Sequencing. By targeting challenging drivers of human disease, we are creating life-saving medicines for cardiometabolic, inflammation, and oncology patients with the highest needs.

Butterfly’s mission is to create access to valuable clinical insights using innovative ultrasound technology, made simple with artificial intelligence, to benefit all patients worldwide. Through the delivery of high-quality, affordable, easy-to-use, intelligently connected ultrasound, Butterfly Network enables better clinical decisions through better information and insight at the point of care. With Butterfly, seeing is knowing – in the hospital, community, or home.

Clinical Assay Innovation (CAI) Biosciences is a consulting firm focused on providing expertise and guidance in the development of Laboratory Developed Test (LDT) and In Vitro Diagnostic (IVD) assays in the areas of Next Generation Sequencing (NGS), Real-Time Polymerase Chain Reaction (qPCR), Immunochemistry, and Clinical Chemistry. Our mission is to provide our clients with best in class assay development services and to insure successful implementations of their projects.

At CAMP4 Therapeutics, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Join us at the forefront.

CAPACITÉS is the subsidiary of University of Nantes, dedicated to the development of research. Specialized in engineering of innovative projects, CAPACITÉS exploits the latest scientific discoveries necessary for the performance of its customers. Springboard to differentiate in the ever-changing markets, areas of activity extend to technological and engineering sciences, human and social sciences and health. The activities of CAPACITÉS have advanced expertise on specific and cross-cutting themes. From idea generation to their implementation, CAPACITÉS impulse with its customers a strong value creation process through the development of R&D of high level dedicated to nine economic sectors.

Capra Biosciences is developing a new technology that will make the manufacturing of chemicals using biology cost-competitive with petroleum-based products. Significant advances in synthetic biology have been made over the past 20 years, enabling a multitude of products with lower environmental impact and potentially better performance than their petrochemical counterparts. However, cost-competitive large-scale manufacturing of these products remains a significant bottleneck to their adaptation. Our technology tackles this bottleneck through an innovative bioreactor design that promises to significantly reduce end-to-end manufacturing costs.

Caption Health has been acquired by GE HealthCare. Follow us at @GEHealthCare and @CaptionCare for the latest updates and healthcare news.

Caranx Medical is a healthcare technology company based in Nice, France, founded by a team of experts including an entrepreneur, a clinician, and a researcher. The company focuses on enhancing access to less invasive medical care through innovative technologies. Its mission is to standardize complex surgical procedures, reduce risks associated with human error, and improve outcomes for patients and healthcare providers. The company specializes in developing intelligent robotic systems to improve surgical precision. One of its key products is the TAVIPILOT, a robotic solution designed for aortic valve procedures. Caranx Medical is also advancing the field with TAVIPILOT Soft, an AI software for real-time guidance during heart valve implantation, which is set for FDA submission in January 2025. The company has achieved significant milestones, including the world's first robotic-assisted heart valve implantation in an animal in April 2024. With a diverse team of over 20 professionals skilled in robotics, software management, and artificial intelligence, Caranx Medical is committed to driving innovation in interventional cardiology and improving patient care worldwide.

CaraVan Biologix is a biotechnology company focused on expanding the life-saving benefits of CAR-T cell therapeutics to the broader cancer patient population by addressing their limitations. Our underlying and core novel technologies enable the development of allogenic treatments for a spectrum of human diseases, including solid tumors and hard-to-treat cancers. Our therapeutic agents are expected to show superior safety profiles, including a low risk for cytokine release syndrome. Importantly, our technology will greatly reduce the complexities of manufacturing that are associated with whole-cell therapies, thereby minimizing the time, cost, and variability risk to facilitate greater access for patients in need.

Delivering cutting-edge cardiac medical devices to clinicians since 1994. CardioCommand Inc., headquartered in Tampa, Florida, is a pioneering medical technology company dedicated to revolutionizing cardiac care. Established in 1994, CardioCommand has established itself as a leading innovator in the field of cardiovascular health, leveraging cutting-edge advancements in medical technology to enhance patient outcomes and streamline medical procedures. At CardioCommand, our mission is to empower healthcare professionals with state-of-the-art cardiac monitoring solutions, ensuring timely and accurate diagnoses while prioritizing patient comfort and well-being. We are committed to advancing the standard of care in cardiovascular medicine through innovation, integrity, and excellence.

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic EngineTM ("Core Technology") for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease.

Contact: contact@cardiosense.com Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI to develop predictive biomarkers for pre-symptomatic disease detection and enable personalized therapy.

Cardiotrack is a disruptive healthcare diagnostics solution that is making healthcare delivery more efficient. The mission of Cardiotrack is to reduce the cost of diagnosis by an order of magnitude through innovation in product design, and enhancements in healthcare workflow. Key challenges faced by healthcare providers include – the high cost of diagnostic equipment and lack of trained professionals, especially in semi-urban areas. Cardiotrack is addressing both these issues through the state of the art medical electronics, data analytics, cloud storage and diagnostics workflow management. Cardiotrack focuses on heart health and has consulted with some of the best medical research institutions in India like St John's Research Institute & Jayadeva Institute of Cardiovascular Science in Bangalore; brought onboard doctors and cardiologists as advisers and is collaborating researchers at the Loyola University of Chicago to deliver a comprehensive diagnostics solution for cardiovascular diseases (CVD). Cardiotrack is a multiple parameter handheld diagnostic device including 12-lead ECG monitor, pulse oximeter and blood pressure monitor integrated with mobile-based practice management solution and cloud backend. Low cost, portability and network-connectivity mean that Cardiotrack may be deployed at the primary care level and the resultant scan of the patient can be delivered instantaneously to a specialist anywhere in the world. This approach leads to efficient use of specialists'​ time, enables early diagnosis of heart patients and thus reduces the need for expensive invasive intervention. YouTube: https://www.youtube.com/watch?v=Tj3EI2iC7RE

CardioWise's non-invasive Cardiac Computed Tomography (cCT) analysis software produces an easy-to-understand 3D image model of the human heart.

CarePoint Solutions: Elevating the IQ of Healthcare Delivery Introduction: Welcome to CarePoint Solutions, where we're committed to revolutionizing healthcare delivery through innovative technology. Our flagship product, Pro-QCP, is a cutting-edge SaaS quality management utility designed to address critical challenges in diagnostic accuracy and clinical lab regulatory compliance. The Challenge: Healthcare systems globally face significant issues with diagnostic errors, leading to adverse outcomes and unnecessary costs. Evolving regulatory requirements further complicate matters, making compliance a challenge for labs while maintaining efficiency. Our Solution: Pro-QCP not only introduces a higher standard for diagnostic quality assurance, but offers a practical and efficient means for clinicians to achieve it. Developed in collaboration with industry experts, our solution streamlines lab workflows, saves time, identifies errors, ensures compliance, and drives improved clinical outcomes and operational efficiencies throughout healthcare organizations. "Pro-QCP is like a Pac-Man that goes through a healthcare system, identifying and correcting diagnostic test errors wherever they are found." Pro-QCP's Key Features and Benefits: - Ensures compliance with challenging new international regulatory standards. - Optimizes a lab's most critical workflow: delivering accurate and timely test results. - Provides actionable information to improve diagnostic processes and mitigate errors. - Prevents needless deaths and adverse events. - Drives downstream efficiencies and economies by improving diagnostic accuracy. - Saves a typical lab hundreds of hours of staff time. - Offers value to stakeholders throughout a healthcare delivery organization. Pro-QCP is a first-to-market solution that meets a critical need in the healthcare industry. From small labs to multinational lab networks, our solution offers value to virtually every clinical setting.

At Caresyntax, we are dedicated to making surgery safer and smarter. Our mission is to converge AI-powered software, devices, and clinical services to help our customers improve surgical outcomes. Our platform, an enterprise-grade surgical intelligence system, is vendor-neutral and equipped with proprietary software, hardware, and advanced AI capabilities. It can ingest and analyze data throughout the surgical workflow, including EMR, video, audio, image, device data, financial and outcomes data, and clinical and operational metrics to capture a complete picture of the surgical pathway. The platform generates insights across the entire continuum of care—before the procedure with surgical workflow optimization, during surgery with real-time clinically relevant support tools, and post procedure with clinical safety modules. The platform also produces data analytics and insights for medical device companies, insurers, and other ecosystem players to innovate and drive the future of healthcare delivery. Headquartered in the US in San Francisco and internationally in Berlin, Caresyntax software is used in over 3,000 ORs globally and aids surgical teams in over 3 million procedures annually. To learn more about how we're transforming surgical care, visit us at www.caresyntax.com.

Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions. Our Website: https://www.caristo.com Follow us on Twitter: https://twitter.com/CaristoHeart

Carta provides advanced genomic testing for IVF. We help IVF parents predict their embryo's disease risk and health outcomes in advance, resulting in improved women's health and healthier babies.

Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterra’s flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery and small molecule analysis. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. For additional information, please visit www.carterra-bio.com.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, mental health and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. IDgenetix is Castle's pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient’s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

CD ComputaBio is a professional computational biology service company. Our service spans across different areas in computational biology, providing access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. We are committed to providing high-quality data and customer service to various industrial and academic customers.

Cancer diagnostic

Cellari enables doctors and non-specialists to take full advantage of recent developments in artificial intelligence. Cellari aims to provide the most precise "active learning model" for biological image segmentation combined with an intuitive and easy-to-use user interface for carrying out complex image related tasks and analytics. An automated statistical testing service ensures statistical validity of clinical and research related results along with unparalleled review and methodology transparency functionalities. Cellari is a proud part of the InnoFounder – Graduate incubator for Cohort 5 of September 2019.

Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.

CellChorus conducts dynamic single-cell analysis at scale. Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) uses visual AI to evaluate how cells exist in motion. CellChorus is a single-cell, visual AI company that is the leader in visual AI for single-cell analysis.

Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company's cloneXplorer and proprietary nanowell plates uniquely integrates both phenotypic and genomic data at massive scale (up to 100,000s of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology. Learn more at www.celldom.com and follow the company's growth @celldominc on Twitter.

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)

Cellibre is a best-in-class manufacturing technology company.. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more. Member: BioMade, Defense Industrial Base Consortium (DIBC)

Cellinfinitybio is a biotechnology company that pioneers massive directed evolution to unlock the infinite potential of cell therapy.

Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.

CELLIX BIO - Founded in 2014, we are the leading drug discovery and development company. We generate our own drug design data before combining the critical power of AI with the creativity of involving proprietary platform technology, Synergix AI, and the expertise of our world-class scientists. This allows us to shorten the pre-clinical drug discovery stage and, in turn, substantially accelerate the delivery of new treatments to patients worldwide. By reducing the number of compounds analysed, we aim to vividly reduce the time and cost of discovering and developing new medicines. Cellix Bio balances Synergix AI plus human creativity in drug discovery.

CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol. We're working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world. Our mission is bold and ambitious and we have the best investors behind us from day 1. We're backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We're also supported by the founder/CEO of Abcam, which pioneered the antibody business.

Cell X is pioneering a revolution in cell processing. At the core of this revolution lies our transformative Celligent platform – an innovative bundling of automation, imaging, data analytics, and machine learning that enables therapeutic researchers to develop consistent, reproducible, and scalable GMP-compliant processes for stem cells and bio-fabrication. Celligent enables the development of safe and effective products by executing the necessary process development and cell manufacturing procedures in a fully documented, compliant way. Successful cellular therapies demand starting with optimized cell sources; and intrinsic variability and heterogeneity among cell sources presents a major challenge. This critical first step of control over starting materials demands the use of quantitative and reproducible standards for cell and clone selection and process management based on critical process parameters (CPPs) in order to achieve products with defined critical quality attributes (CQAs). Backed by a highly experienced team, Cell X automates cell processing in diverse cell culture applications spanning mesenchymal stromal/stem cells (MSCs) and exosomes, induced pluripotent stem cells (iPSCs), hematopoietic stem cells (HSCs), connective tissue progenitor cells (CTPs) and tumor-infiltrating lymphocytes (TILs) as well as other progenitor cell types. We are dedicated to advancing the promise of cellular therapies for innovators and patients alike, ultimately making cell therapies more accessible to millions of patients worldwide. 

Centaur Labs is the modern data labeling solution for AI innovators across the healthcare landscape. With an expert crowd of 50k+ labelers and a gamified app to incentivize and quality-control them, our scaleable labeling methodology ensures high-quality labels in as little as 24 hours.

Cercle is an AI technology company with the mission to advance healthcare for all women. With AI, we harness anonymized, diverse and reliable biomedical and genomics data from around the world to deliver unprecedented and secure healthcare insights. The Cercle™ Biomedical Graph is a first-of-its-kind knowledge graph. It uses AI to analyze billions of anonymized data points securely drawn from hospitals, clinics and research labs from all over the globe. We're turning raw, unstructured and disconnected biomedical and genomics data into clear insights for doctors, hospitals, research centers, pharmaceutical companies, labs and clinics so they can treat patients more effectively. That's how we support innovation and advancements in treatments and healthcare outcomes across the entire healthcare ecosystem. Women's health is the most underserved healthcare market, which is why Cercle's first focus will be fertility and IVF. We're proud to beta launch Luce, a fertility companion for women and doctors that analyzes data from thousands of treatment cycles to help people make more informed decisions for their fertility journeys. Cercle's suite of products includes: — Data access tools: Researchers and lab directors can query and visualize structured biomedical and genomics data to accelerate health innovation. — Modeling and insights products: Advanced modeling tools help healthcare providers with financial and operational strategies. — Tools for clinicians: Doctors get personalized care insights and predictive treatment outcomes based on Real World Data and Real World Evidence. — Patient companions: Patients get clear, data-driven insights that make it easier to understand their health and make informed decisions with their doctors. Cercle is built by medical professionals, molecular biologists, data scientists, engineers and business entrepreneurs dedicated to unlocking a world where everyone feels informed, empowered, and in control of their own health.

At CereHealth, our mission is to revolutionize healthcare through the power of artificial intelligence. We are committed to improving patient outcomes and enhancing the efficiency of clinical practices by providing cutting-edge AI-driven Clinical Decision Support Solutions (CDSS). Our purpose is to bridge the gap between data and insights, enabling healthcare professionals to make informed and precise decisions at every critical juncture. By harnessing the potential of AI, we aim to empower medical experts with real-time, evidence-based recommendations that promote accurate diagnoses, personalized treatment plans, and optimize patient care. Driven by our dedication to innovation and integrity, we envision a future where healthcare providers can seamlessly integrate AI into their workflows. Through continuous research, collaboration, and advancements in AI technology, we strive to be at the forefront of CDSS, setting new standards for excellence in healthcare decision-making. We are unwavering in our commitment to privacy and security, ensuring that patient data is treated with the utmost confidentiality and adhering to the highest standards of compliance. Our solutions are designed not only to support medical professionals but also to engender trust among patients, knowing that their well-being remains at the heart of every AI-driven recommendation. By working hand in hand with the medical community, we aim to foster a healthcare landscape where AI augments human expertise, leading to faster, more accurate diagnoses, reduced medical errors, and ultimately, improved patient outcomes. At CereHealth, we are dedicated to shaping a healthier tomorrow through the synergy of AI and medical wisdom.

Transformation. It's a word we hear a lot—the moment when a discovery leads to an innovation that fundamentally changes our world. There's a backstory to transformation—one that takes place in labs and research facilities by people who work tirelessly for years to reach that a-ha moment. Cerillo understands the passion, tenacity and investment that come before transformation. Our technology is laser-focused on helping you achieve greater efficiency and agility in your research. But more than that, it's designed to illuminate possibility by letting you view the same problem from new angles. Stratus, our portable plate reader, is helping scientists anticipate and creatively solve human challenges from the palm of their hand, giving them the freedom to take their work out into the world. And that's just the beginning. Our team is committed to constant innovation in our lab to make discovery in your lab easier. Think of us as the proactive lab partner you didn't know you needed, clearing the way for you to reach that transformational moment that changes the world for good.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett's esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient's tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett's Esophagus is the world's first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett's esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

Certis Oncology is a life science technology company committed to realizing the promise of precision oncology. Certis was founded in 2016 with a singular purpose: to bring certainty to the fight against cancer. Their science delivers clinically relevant, predictive data and they are located in the heart of San Diego's Life Sciences center, Sorrento Valley.

CHA Bio Group is continuing its challenge to become the best in various initial achievements in the bio and healthcare fields. We are developing and producing advanced biopharmaceuticals, including cell and gene therapy products and vaccines, based on our global R&D capabilities, such as our unique ‘CHA Bio ecosystem': Academic, Research, Medical Network, and Bio-Industry Business, the world's largest cell library, and our independently developed vaccine adjuvant platform. We will leap forward as a true global bio company centered on the third-generation CGT CDMO and global healthcare business.

CHARM Therapeutics is discovering and developing small molecule medicines against difficult-to-drug targets with our proprietary 3D deep learning-enabled platform, DragonFold. Powered by the first high throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM seeks to deliver innovative approaches to create life-changing therapies for patients.

ChemDiv, a fully Integrated Target-to-Market Contract Research Organization (CRO) headquartered in San Diego, CA USA. ChemDiv provides integrated drug discovery and early clinical development deliverables by extracting added value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital. - 25 years experience and 2500 customers worldwide - Premium R&D CRO based in USA with global reach - Seasoned project managers - Extensive Academic partnerships - Flexible business models - Competitive pricing options - Industry's largest ever-greening stock compound inventory - Ongoing investments in novel proprietary chemistry and discovery platforms One of the oldest CROs in the industry, ChemDiv provides Integrated Discovery outSource™ solutions that cover the complete range of disciplines needed to bring new drugs for treatment of CNS, oncology, inflammation, metabolic and infectious diseases from target to candidate and through clinical Proof of Concept to the market. ChemDiv champions collaborative development models with co-investors to rescue under-exploited R&D assets for pharmaceutical and biotech partners. #pharma #biotech #chemistry #screening_Libraries #drug_discovery_services

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. They recently raised Series B and Series C financing from The Column Group and NextTech Invest. Circle Pharma design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. They do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). They have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Circle Pharma workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. They deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.

CircNova, Inc. is a biotechnology company that leverages our unique AI NovaEngine™ to generate, analyze and identify circular RNA for therapeutic development.

Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth. Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citrine empowers product experts with vanguard AI technologies. With no background in data science, product experts apply Citrine to deliver next generation products faster than any other time in history. Citrine’s software learns easily from the knowledge of its users and their idiosyncratic data to enhance all aspects of the product lifecycle across all industries with a physical product. Citrine’s users increase supply chain efficiency, rapidly improve product quality, enhance customer experience, expand product reach and increase the velocity of product delivery. With Citrine, product experts unlock the capability to solve our society’s greatest environmental and productivity challenges. Citrine's customers include Eastman, Panasonic, Grace, LyondellBasell, LANXESS, Morrow Batteries and some of the biggest and most respected names in the materials and chemicals and CPG industries in Asia, North America, and Europe. For more information visit our website at https://citrine.io.

Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

CJ Bioscience Global No.1 Microbiome Company CJ Bioscience is pioneering development of next-generation biopharmaceuticals for microbiome health with its leading edge in the field of ‘Wellness'. We aim to provide healthcare solutions for unmet medical needs by examining the relationships between human microbiomes and various diseases. In addition, CJ Bioscience, which uses leading world-class bioinformatic analysis technology, will discover promising candidates that can be used in the treatment of incurable diseases, and accelerate the development of new drugs utilizing our ‘Ez-Mx™ Platform' to become the global No. 1 microbiome company. Microbiome We plan to enter clinical trials (Phase 1) of a new drug development pipeline for treatment of immuno-oncology, autoimmune, and CNS (Central Nervous System) diseases and to promote technology export through joint research with Big Pharma. Also, we are constructing a ‘Ez-Mx™ Platform' by expanding on cohort studies (comparative disease research) and securing global microbiome big data. The next generation of genomic analysis We plan to expand our business area from next generation sequencing (NGS)-based microbiome genomic analysis to microbial infection diagnosis. We will further upgrade our state-of-the-art NGS and bioinformatics (BI) total solution services. We are expanding the global business capabilities of EzBioCloud, a global standard bioinformatic analysis service made for researchers combining a curated microbiome database and artificial intelligence (AI) technology, and TrueBacID, the world's first genome-based infection diagnosis service. In addition, through the global launch of Gut Inside, an intestinal.

Clarapath is a medical robotics company automating the laboratory. Our first product is focused on automating the microtomy station in pathology. Our vision is to innovate, standardize, and digitally transform anatomic pathology through higher quality lab medicine, more robust safety standards, increased lab throughput, while lowering laboratory costs and labor related delays.

Clarity Genomics provides consulting services for microbiome-metabolome data insights in clinical research. Using our global network of specialists and regional cloud storage and computing, we provide expertise in collection and preparation of microbiome and metabolome samples, data processing and analysis. We work closely with our clients to offer biological insights that empower the development of new microbiome products and therapies. Partnerships with leading research institutions ensure that your project receives relevant information utilizing technologies and techniques on the forefront of innovation.

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

Clear Guide Medical is a leader in next-gen medical imaging fusion and navigation technology. Our vision-based approach has been introduced in a family of clinical guidance products, including the CLEAR GUIDE SCENERGY for instrument guidance and SCENERGY FUSION for ultrasound and CT/MRI image fusion. Our products make minimally-invasive interventions like biopsies, ablations, pain injections, and peripheral nerve blocks efficient and cost-effective. The company is a privately-held spinout of the Johns Hopkins Medical Institutions and The Johns Hopkins University based in Baltimore, Maryland.

Our vision is to redefine the boundaries of neuroscience with minimally invasive technologies to enable unparalleled precision, enhance patient outcomes, and forge a new era of highly targeted neurotherapies for a healthier world.

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. Digital therapeutics under development on our platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, cardiology and immunology. Consistently named a best place to work, we foster an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in our mission to provide patients everywhere access to safe and effective prescription digital therapeutics. NOTE: Fake job advertisements and offers are increasingly appearing on the internet. If you have encountered a job posting or have been approached with a job offer that you suspect may be fraudulent, we strongly recommend you do not respond and report it to the Federal Trade Commission and to recruitment@clicktherapeutics.com. Other than your email address or telephone number, which you may provide via a job application portal, Click Therapeutics will never ask you to provide personally identifiable information about yourself (such as a Social Security Number or Driver’s License Number) via a messaging application.

Clinerion, a wholly owned subsidiary of TriNetX LLC, accelerates clinical research and medical access to treatments for patients. We use proprietary, patented technologies for analysis of live electronic health record (EHR) data from our global network of partner hospitals to generate real-world data (RWD), which can be used for investigation into disease epidemiology, the patient journey and outcomes, and patient care metrics. Clinerion's Patient Network Explorer platform radically improves the efficiency and effectiveness of clinical trials by offering data-driven protocol optimization, site feasibility evaluation, and search and identification for patient recruitment – in real-time. Among other uses, we provide solutions for increasing diversity in clinical trials and identification of rare disease patients. Clinerion's new Federated Machine Learning Platform enables the training and validation of machine learning (ML) algorithms on our global RWD network. Apart from the contributions to drug development this platform targets to develop preventive care for patients before they reach a critical stage. Clinerion operates on the principle of "privacy by design" and complies fully with international patient privacy and data security regulations. Clinerion is headquartered in Switzerland. Clinerion website: www.clinerion.com Clinerion's Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

Clinion is a leading global clinical trial company renowned for its award-winning solutions that drive innovation and excellence in the field of clinical research. We implement cutting edge technologies like AI/ML and GenAI to accelerate clinical trials for better outcomes. Our unparalleled expertise empower pharmaceutical, biotechnology, and medical device companies to conduct clinical trials more efficiently and effectively. Join us in revolutionizing the future of clinical trials and making a lasting impact on global healthcare. Facebook : https://www.facebook.com/clinion Twitter : https://twitter.com/clinion YouTube : https://www.youtube.com/c/Clinion Instagram : https://www.instagram.com/clinion_ai/

Clinomics provides early diagnosis of cancer/diseases based on genome and pursues to overcome aging and diseases through liquid biopsy and Multi-Omics technology.COVID-19: EUA (02/2021)

Cloudbyz is focused on building cloud-based products and solutions for life sciences customers, and help them innovate drug development and research to bring therapies faster to market which improve patient health and saves lives. Our innovative digital solutions for Pharmaceuticals, Contract Research Organizations (CRO) and Medical Devices companies helps to digitize research, drug and device development and commercialization. Our suite of products include: 1. Cloudbyz CTMS 2. Cloudbyz CTBM 3. Cloudbyz eTMF 4. Cloudbyz EDC, ePRO & eCOA 5. Patient Recruitment 6. Cloudbyz Safety & PV 7. ClinicalWave.ai (AI based platform for Life sciences organizations) Cloudbyz CTMS, eTMF, EDC, and Safety & Pharmacovigilance are built 100% native on Salesforce cloud platform for sponsors, clinical research organizations (CRO), and Clinical Sites. Cloudbyz Clinical Research Solutions are flexible and scalable to enable to manage and collaboration on clinical trial operations while the intuitive, straightforward design allows rapid deployment with a very intuitive and easy-to-use cloud-based solution. Cloudbyz ITPM offers 360° view and real-time visibility across IT planning, execution, and operations and helps organizations to achieve agility, velocity, innovation, and collaboration across IT and business. Cloudbyz ITPM helps CIO, PMO, and IT leaders to visualize the IT landscape, capability mapping, investment, and operational health in real-time and better align IT initiatives with business.

We're a dedicated team of engineers, data scientists, doctors, innovators, and creative thinkers from across the globe. We're united in our drive to use technology to simplify healthcare and make it work better for everyone involved. We unify all data sources and other systems together for a complete picture. We automate for efficiency throughout. Clinical, operations, and financial results are collected and coordinated like never before.

Cloud Pharmaceuticals is a pharmaceutical company that specializes in in silico therapeutics, revolutionizing drug discovery and development processes.

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.

Coding Bio unites a high throughput wet lab and ML platform to screen, build, and deliver fully-assembled modular therapies like CARs and BiTEs in only months.

Bio Information is energy! COGNANO, Inc. is a venture to aim for computer-supported drug discovery. The big VHH data obtained from our own alpacas will lead us to a new drug discovery platform. Our goal is to optimize drug designing/development.

Cognivia is an innovator of analytical tools to optimize and accelerate the clinical development of new medicines. The privately held company was founded in 2013 by longtime colleagues with decades of experience in the pharmaceutical industry who set out to tackle some of the most challenging issues that prevent drugs from reaching the marketplace. Cognivia helps lessen risk and helps increase clinical trial success. It can help reduce the variability of study data by 30 percent. This can lead to fewer patients needed in a study, equating to less cost and time. The company offers Placebell©™, a solution that improved clinical trial assay sensitivity by characterizing and managing the individual placebo response in a variety of disease states where the placebo effect masks the true efficacy of potentially important therapies.

Cognoa innovates solutions for child developmental health. We build breakthrough products like Canvas Dx, the first and only FDA authorized autism diagnostic for children ages 1.5 to 6 years that uses responsible AI to empower doctors to quickly, accurately, and fairly diagnose developmental risk without bias. Our digital solutions are child centric and designed to find, assess, and treat developmental concerns early, within the time windows that will yield the optimal outcomes. Our proprietary "whole child" approach to AI fuels our pipeline of diagnostic and therapeutic products for autism, speech and language, ADHD, childhood anxiety, and more. For more information, visit www.cognoa.com.

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

Collaborations Pharmaceuticals, Inc. works on drug discovery for rare and neglected diseases. We develop and license our AI software as well as provide fee for services for pharmaceutical and consumer product services. To date we have won with collaborators $23.5M in grants since 2016.

Collaborative Drug Discovery's CDD VAULT is a hosted biological and chemical database that securely manages your private and external data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy-to-use web interface. The available modules within CDD Vault include Activity, Registration, Visualization, Assays, AI, Automation, Curves, Inventory, and Electronic Lab Notebook (ELN). Each module is designed to optimize various aspects of research and data management, enhancing the overall efficiency and productivity of scientific workflows. CDD Vault is a system your entire team can actually use! Engineered for Ease of Use CDD Vault allows you to enjoy the benefits of large enterprise systems without the administrative burden or expense. Modern Cloud Solution Saves Money CDD Vault is affordable to academic laboratories, research foundations, and small companies. Beats Juggling Spreadsheets of Screening Data! Eliminates the Risk of Data Loss CDD Vault provides a secure environment to collect all your compound and screening data. Get Better Results from Unified Data CDD Vault consolidates all your compound and screening data in one place. This makes analysis easier, more consistent, yielding results more quickly. Securely Store Experimental Data in a Private Hosted Vault Data Migration is a Snap CDD Vault can provide easier access and better management of your existing data too. Safely Share Data CDD Vault allows you to selectively share data in real time with your designated researchers in your own lab or across the globe. Security is Built-In - CDD Vault is protected with SSAE 16 Type II certified cloud storage on locked and guarded hardware. https://www.collaborativedrug.com/pages/benefits CDD VAULT from Collaborative Drug Discovery https://www.collaborativedrug.com

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

The science of genetics. The business of discovery. Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

At ColVisTec, we work with the world's leading manufacturers in the paint, pharmaceutical, plastics, and chemical industries. Our team of highly knowledgeable engineers and scientists support them with a reliable and industry-ready inline UV-Vis spectroscopy.​ ​ By adding inline UV-Vis spectrophotometry devices onto the assembly line, we can measure the production output in real-time. In addition, it opens fantastic opportunities for productivity as well as quality gains, leading to a huge stand-alone benefit for your factory when implemented into the context of digitalized manufacturing: Industry 4.0. Our technology can be customized for a wide variety of processes, allowing flexible hardware configurations, offering data output in different formats, and excellent integration with the software solutions already in place. We take pride in our extensive customer support and provide a full menu of training options to secure a smooth transition from off-line measurement to fully automated inline solutions. ​ From our headquarters in Berlin, Germany, we support our product line worldwide and work in close cooperation with other process machinery manufacturers to provide complete solutions when customers are in the market for new plants. Most often our technology is fitted to the existing manufacturing facilities, boosting their productivity and quality. We don’t see ourselves as suppliers of hardware, our aim is to provide unique solutions that are specifically required by your process. ​ Our company was founded in 2009 and is now co-funded by the Horizon 2020 program of the European Union.

We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first clinical development programme is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. We want to transform the patient experience in mental health care.

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Computomics was founded to bring the latest bioinformatics discoveries to industry application, facilitating global agricultural development.Crops: Parse large genomic data sets for plant breeders, deliver breeding recommendations, and provide molecular biology insight to reduce crop area requirements.Animal Health: Assemble and annotate genomic data from your species of interest, compare time-series data and visualize genomic variation in insightful ways.Metagenomics and Microbial Genomics: Analyze complex microbial communities and discover new organisms and metabolic pathways in a variety of samples.

Conceivable has developed the world’s first fully automated IVF lab. Our end-to-end reinvention of today’s largely manual, artisanal labs delivers new levels of precision, quality, and scalability. Simultaneously, Conceivable brings the innovation of modern cell therapies to IVF. We are already exceeding the clinical benchmarks of today’s best IVF labs. Worldwide 95% of the infertile population–and 80% in the United States–don’t have access to IVF. Conceivable exists to change this. By automating the IVF lab we will vastly broaden the availability of this Nobel Prize winning therapy, improve results, and meet the demands of millions of infertile people wishing to achieve the dream of becoming parents.

Their mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, healthcare providers, and medical societies.

Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.

Science has a problem. There are many suppliers and many scientists. Finding the right supply at the right price is hard, and if you're a life science company, you want to be able to get your customers the best product. We are creating a better vision for scientists to conduct science and make new discoveries. Located between two of the most prominent universities in the world, Harvard University and Massachusetts Institute of Technology, our startup has access to some of the most talented biotechnology, life sciences, and medical/health professionals in the world. https://linktr.ee/conduct_science

Congenica is a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale. We drive Precision Medicine and help reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide. Congenica’s Platform is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, and is uniquely placed to drive ubiquitous use of complex data in routine clinical care. Our products and services are consolidated on one single scalable, automated analysis and diagnostic platform that encompasses inherited disease, somatic cancer, pharma insights and pathogen surveillance. Congenica was founded based on pioneering work at the Wellcome Trust Sanger Institute and the UK NHS. We are the exclusive clinical decision support partner for the NHS Genomic Medicine Service and have a global footprint supporting leading international laboratories, academic medical centres, hospitals and biopharmaceutical companies.

CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs. The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available. The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).

Consegna Pharma Inc. is a specialty pharmaceutical company with a mission to create best-in-class long-acting medications.

Consone AI a disruptive technology platform targeting how decisions are made in the drug development process. Accelerating new medicines to market, reducing cost, reducing preclinical toxic trials, time and environmental footprints. The Consone AI platform will empower user decision making by successfully predicting toxicological effects and viability of new drugs.

MAVEvidence is the premier functional evidence resource for the clinical genetics community. MAVEvidence delivers increased productivity and time savings through comprehensive curation, rigorous analysis, and clear presentation of functional evidence derived from high-throughput studies of genetic variants. The MAVEvidence platform contains more than 187,000 pieces of evidence across 125,000 genetic variants, and is continually updated with data from the latest functional studies.

Convalife Pharmaceuticals is an innovative pharmaceutical company that specializes in drug research and development for tumor diseases. They are dedicated to developing innovative drugs and focus on antibody biopharmaceuticals and small molecule treatments.

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

Convergent R.N.R (CRNR) developed a transformational AI driven robotic radiation platform that was exclusively designed to significantly reduce non-therapeutic dose to adjacent critical structures, disrupting a stagnant radiation therapy/surgery equipment market. The uniquely converging low energy x-ray beam fulfils the un-met proton beam therapy promise, for a less toxic (to nearby organs) radiation solution, at a fraction of the cost, while reducing total cost of ownership by eliminating the need for a concrete bunker.

Conversio Health is an innovative chronic condition management company focused on COPD and Asthma Disease Management. They aim to improve outcomes, prevent hospitalizations, and reduce the total cost of care for chronic respiratory conditions.

CoraVie Medical's implantable, continuous blood pressure monitor informs treatment decisions to improve lives. The end to end solution improves patient compliance to monitoring and improves blood pressure reliability and actionability. By monitoring trends over day and night, CoraVie enables timely notification of changing health status.

About Coreline soft We develop AI-based imaging diagnosis package, specializing in lungs. This includes lung cancer screening(LCS), COPD quantification, and coronary artery calcification (CAC) systems, we call it B3 systems, covering the 3 big diseases in thoracic imaging. More in-depth lung diagnosis products with analysis such as texture analysis for ILD/IPF and pneumonia detection including COVID-19 are soon to be expected.   √ The Official solution provider for the nationwide lung cancer screening program in Korea (K- LUCAS) from 2017, which is the 2nd state-level-reimbursed LCS program following the US from 2015 √ The Official solution provider of 4-ITLR project by the Nelson Team (Erasmus MC and iDNA in the Netherlands), which is a large early detection LCS Trial-based on B3 system. Two hospitals in Germany, DKFZ Heidelberg and Univ Hosp of Essen, are the members of this trial and our systems will be implemented in these hospitals from 2021. √ Imminent Official solution provider for the German Trial by multi-university hospitals which is a pilot project to prove a national support necessary for LCS in Germany. √ Our COPD systems are used by European customers such as NZ Leuven Belgium, Leicester Univ UK, Parma Univ Italy obtaining the appraisal as the best of breed for early detection, phenotyping, surgery support, and etc.

CorVista Health is transforming cardiovascular care with the CorVista System, a non-invasive point-of-care diagnostic technology, that shortens the path from symptoms to diagnosis, empowering earlier treatment and better patient outcomes. The CorVista System leverages proprietary machine-learned algorithms and robust clinical data to deliver results providers can trust. For more information visit www.corvista.com

Cortechs.ai develops and markets cutting-edge imaging solutions that are used by radiologists, neurologists, and oncologists in hundreds of clinics and research centers around the world. The Cortechs.ai team includes scientists, engineers, business professionals, and clinical specialists working towards the common goal of improving the diagnosis and treatment of patients with neurodegenerative disorders and cancers. Cortechs.ai's​ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.

Cortex aims to transform the diagnosis and treatment of atrial arrhythmias by providing insight into each individual patient's disease pathophysiology. The OptiMap™ System is a 510k cleared, electrographic flow mapping solution designed with AI, enabling physicians to See What Matters.

We believe Cells can theoretically produce almost anything, from fabrics to food, fuel and medicines. Designing cell-factories is hard, but our tools and machine-learning models can make it easier. Our mission is to ultimately help replace traditional farms and factories for a more sustainable world.

At Crane Biosciences, we enable RNA treatments for incurable diseases. We are based at Imperial College London and backed by Norrsken, InnovateUK, Entrepreneur First, and Creative Destruction Lab (University of Oxford).

Reinventing drug development from the ground up and making on-demand oligonucleotide therapeutics possible.

Cumulus Neuroscience is a global digital health company focused on advancing neuroscience clinical trials and research. They collaborate with leading global pharmaceutical companies to meet the industry's complex clinical trial needs. Cumulus Neuroscience offers a unique career and is known for its innovative assessment platform for identifying brain disorders.

CurifyLabs is a Finnish healthtech company developing solutions for manufacturing personalized medicines in pharmacies and hospitals. CurifyLabs is revolutionizing the way personalized medicines are created. We provide innovative technology that enables the automation of compounding—transforming a traditionally manual, time-intensive process into a streamlined, efficient, and accurate system. The CurifyLabs' Compounding System Solution (CSS) is an automated pharmaceutical compounding platform for non-sterile dosage forms, including tablets, troches, liquids, suppositories, vagitories, ointments and capsules. It enables better treatments for patients and improved efficiency for pharmacies and hospital pharmacies. In addition to cost savings, it ensures high manufacturing standards at the point of care through in-process quality control. The CSS is a user-friendly platform consisting of: GMP manufactured excipient bases, compounding robotics, integrated quality control tools, software and a comprehensive formulation library to meet versatile compounding needs of pharmacies.. CurifyLabs’ CSS technology is currently in use for patients by customers in Europe and US. The CurifyLabs Compounding System Solution offers an easy-to-use, turnkey solution for pharmacists and hospitals, making personalized medication production faster, safer, and more accessible to patients in need. CurifyLabs was founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius.

Cyclarity Therapeutics, Inc. is pursuing a mission to treat, cure, and reverse atherosclerosis. The company aims to deliver simple and affordable therapies for cardiovascular disease and other chronic diseases of aging. Cyclarity is continuing to develop technology to treat the underlying causes of age-related diseases.

Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering a new solution where conventional therapies have fallen short.

Cyrus Biotechnology is a biotechnology company that specializes in protein engineering and drug discovery through computational biology.

Cytonus is reinventing drug-discovery and drug-delivery by questioning the principled approaches of pharmacodynamics (physiological effects of drugs) that has failed patients since the start of medicine. With a revolutionary platform technology called the Cargocyte, we believe the days of flooding the body with medicines with a hope and prayer to effect disease is not only antiquated, it is scientifically flawed. With a combination of precision drug delivery and in-vivo drug production the Cargocyte platform enables science and medicines to new level of effectiveness without compromising safety for patients.

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive Flex-NK™ bispecific antibody and iPSC-derived, TALEN® gene-edited NK-cell platforms. FLEX-NK™ bispecific antibodies are built on a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology. The company is also developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. ​ These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as relapsed multiple myeloma. Clinical studies are expected to initiate in 2023.

Dandelion Science is a US-Swiss Generative Neuromodulation™ company, committed to advancing precision therapies for vision and brain disorders. Led by a world-class team, Dandelion's mission is to enhance the lives of people affected by these conditions through the integration of advanced generative technologies and deep scientific expertise. The company boasts extensive intellectual property and has received prestigious funding from the US National Institutes of Health and the Swiss Innovation Agency.

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes. Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).

The BIOVIA portfolio integrates the diversity of science, experimental processes and information requirements, end-to-end, across research, development, QA/QC and manufacturing. Capabilities include Scientific Informatics, Molecular Modeling/Simulation, Data Science, Laboratory Informatics, Formulation Design, BioPharma Quality & Compliance and Manufacturing Analytics.Subsidiaries: Accelrys Ltd, Synomics Ltd, VelQuest Corporation, others.

Резидент инновационного фонда Сколково, Data MATRIX предоставляет услуги по исследованию рутинной клинической практики (RWE) с использованием российских и зарубежных датасетов, обработке данных и биостатистике в клинических исследованиях и разрабатывает программные продукты для клинических исследований. В портфеле компании более 200 проектов для фармацевтических и биотехнологических компаний и CRO. Среди продуктов Data MATRIX такие приложения, как EDC, IWRS и ePRO, онлайн-инструменты для врачей по прогнозированию и оценке эффективности терапии. Компания является членом профессиональных сообществ CDISC, ACDM, SCDM.

DayTwo is leading the charge in personalized nutrition through cutting-edge microbiome analysis. Our mission is to empower individuals to take control of their health by understanding and optimizing their unique gut microbiome. About Us: We specialize in precision health through microbiome-based insights that drive personalized dietary recommendations. We decode the intricacies of the microbiome and translate it into practical solutions. Services: -Microbiome analysis for personalized nutrition optimization. -Predictive dietary recommendations based on individual microbiome composition. Why Choose Us: -Advanced technology: State-of-the-art sequencing methods (full shotgun) and proprietary algorithms -Supported by science: Microbiome insights combined with 25 years of diverse patient data, bolstered by research published in prestigious journals such as Nature, Cell, JAMA, and Diabetes Care -Largest collection of data: World's largest high-resolution sequenced data set of over 90,000 samples -Personalized approach: Recommendations based on each unique microbiome profile Join us on the journey to better health and unlock the potential of your microbiome with DayTwo. Connect with us to learn more!

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!

Deciphex is building a global network of AI empowered pathologists, ensuring accessible, innovative pathology services that improve patient outcomes. The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload. We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.

Deep 6 AI is a clinical trials software company based in Pasadena, California, founded in 2016. The company focuses on accelerating patient recruitment and enhancing clinical research through AI-powered analysis of real-world clinical data. In March 2025, Deep 6 AI was acquired by Tempus, further integrating its capabilities into Tempus' healthcare ecosystem. The company specializes in AI-powered patient matching, which analyzes both structured and unstructured electronic medical record data to identify eligible patients for clinical trials. Its platform connects healthcare organizations, researchers, and life sciences companies, streamlining trial workflows. Deep 6 AI also generates real-world evidence to support rapid clinical trial feasibility analysis and data-driven protocol design, utilizing natural language processing and machine learning to process data from over 25 major healthcare organizations.

Deep Apple Therapeutics is writing a new playbook for drug discovery, leveraging a powerful combination of cryo-EM enabled structural biology, AI-powered pocket extraction, and more. The company is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders.

DeepCure is transforming the field of small-molecule drug discovery, by delivering better drugs in a faster and cheaper way. The company was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. DeepCure does not use AI to simply generate a profile of the target candidate profile (TCP), but instead re-engineers drug discovery to deliver transformative results.

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

DeepHealth is RadNet's AI-powered health informatics subsidiary, created to empower breakthroughs in care delivery. The heart of its portfolio of solutions, the DeepHealth OS, is a cloud-native operating system that orchestrates all data to drive value across the enterprise. DeepHealth aims to elevate the role of the radiologist, beyond radiology and across the entire care pathway. It empowers all users across the care continuum with personalized workflows to make work easier and more meaningful. DeepHealth leverages advanced AI technologies in breast, lung, prostate, and brain health, as well as operational efficiencies to create end-to-end efficiency across the enterprise.

Deep Lens is a digital healthcare company focused on enabling faster recruitment of the best-suited cancer patients for clinical trials at the time of diagnosis using VIPER. Deep Lens' AI-driven cloud platform gives care teams, trial coordinators and oncologists visibility into all available trials and the ability to collaborate on groundbreaking cancer research across all cancer types.

DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform's features and data.

We are a big-data and analysis company focused on enabling reproducibility and predictability in chemistry. With machine learning (ML) and AI powered products, SmartChemistry® empowers the chemist to design, experiment and understand their chemistry on an unprecedented scale. Utilising an advanced knowledge base that combines reaction data, real time sensor data and outcomes, SmartChemistry® enables access to a higher level of experimentation in the chemistry laboratory.

DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Headquartered in Novi, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Called SoftVue™, and featuring proprietary TriAD™ (triple acoustic detection) technology, the system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. This is something no other ultrasound system, currently available, can do. SoftVue has received 510(k) clearance from the U.S. Food and Drug Administration for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Formed in 2010 as a spin-out of Karmanos Cancer Institute in Detroit, MI, Delphinus is committed to creating improved imaging methods that assist medical professionals better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, and without concern of radiation or discomfort.

DermaDetect is an AI driven software which enables remote diagnosis and treatment of skin disorders. Based on the latest technology, the system helps health care providers grow the efficiency of their workflow, profitability of their clinic while significantly improving patient care. Based on intelligent software, the platform integrates easily with existing systems, is easy to use, accessible 24/7 and has an attractive pay-per usage pricing model.

Now cleared by the U.S. Food and Drug Administration (FDA), DermaSensor equips physicians with immediate, accurate, and objective results that improve skin cancer detection through data-driven breakthrough technologies.

Detect builds tools that empower people to understand their health and make informed, timely decisions. Led by Founder Dr. Jonathan Rothberg, the Detect team is redesigning the future of healthcare with the power of technology. Detect wants to make fast, accurate diagnostic testing as routine as taking your temperature and as accessible as telemedicine.

Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 

We want to provide people living with diabetes with an intelligent therapeutic system to regulate blood glucose. This project was initiated in 2011 by the CERITD (Centre d'Études et de Recherches pour l'Intensification du Traitement du Diabète) in collaboration with the CEA LETI. After the success of the clinical trials in 2014, we created Diabeloop to bring the project to market and make it available to the largest number of people. Since spring 2021, DBLG1 System, the first automated insulin delivery device, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands and France.

DIAGENS is a Hangzhou-based biotechnology firm, providing in-vitro diagnostic (IVD) products and other medical equipment.

Diag-Nose.io, founded in 2020 and headquartered in Melbourne, Australia, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.

Differential Bio is integrating scale-down experiments with AI-based modeling to optimize how industry-relevant microbes grow ("biomass fermentation") and produce ("precision fermentation"). By optimizing bioprocesses and growth conditions, the company is not only increasing their clients' R&D efficiency but alsodramatically improving bioproduction outcomes such as yield, cost efficiency, and product quality.

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

Digi.Bio is bridging the digital and biological world through microfluidic automation and AI. We develop programmable microfluidics platforms, integrated with sensor and AI, to make biology easier to engineer.

Digital Diagnostics is an Iowa-based AI diagnostic platform that offers solutions such as image analysis and EMR integration for the healthcare industry.

Harnessing the immune system to reimagine cancer therapy

Diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, and cell and gene therapy.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

Pionner and leader in crop innovation software, since 1984, managing up to 250K agronomic trials per year. Doriane empowers your agronomy department in its digital transformation. Optimize your data, automate your workflows, and make agile decisions! We support innovation in agronomy—whether in the field, lab, or office—to tackle environmental, economic, and human challenges. We offer digital solutions to collect and enhance data for better decision-making. Our goal is to help agronomy teams adopt practices that are more effective, efficient, open, and resilient. Leverage our extensive experience in project management, technology complexity, cyber-security compliance, and evolving scientific knowledge. We bring our full ambition to every project, working closely with customer teams. Our Customer Success Service is fully engaged throughout the project lifecycle to ensure maximum user adoption. Choosing Doriane means more than just acquiring new software; it's embarking on a digital transformation journey with a partner who supports you at every stage to maximize your benefits. Bloomeo agro-testing software manages the evaluation of varieties, inputs, biosolutions, or practices with a systemic approach, emphasizing the environmental context of field data. Bloomeo BioSolutions evaluates the conditions under which a biosolution performs optimally. Bloomeo Product Development software supports product development activities in agronomy: aligning product design with market segments, managing multi-environment trials, standardizing data collection, and optimizing team collaboration. RnDExperience software supports all stages of the breeding process, from crossing to selection and evaluation. Our motto is “Agronomy driven by data!” and stakeholders worldwide appreciate making informed decisions based on meaningful information. Let's discuss your project: https://www.doriane.com/book-a-demo

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. Combining a workflow and data platform with best-of-breed applications, we offer the first true end-to-end solutions for biology, chemistry, formulations, data management, flow cytometry, and more. Trusted by more than 2 million researchers from the world's leading biopharma, chemicals and materials enterprises, and academic institutions, we are dedicated to working with the scientific community to help make the world a healthier, cleaner and safer place to live. Learn more about our platform and products, including GraphPad Prism, Geneious, SnapGene, Protein Metrics, LabArchives, and more, at https://dotmatics.com.

As a nonprofit engineering innovation company, Draper serves our nation's interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers' needs and to deliver new capabilities to them.

Founded in 2014, our company pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the world's first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps. Our founders are all physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards. Additionally, our product FDA-cleared.

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

DynoSense Corp. is a medical technology founded by successful high tech veteran, with a mission to “innovate best in class products and services for better, longer, and healthy life that are integrated, accurate, secure, elegant, and simple to use”. We call it “Innovation For Life”.

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy.Using machine learning and quantitative high-throughput in vivo experimentation, they are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

EchoNous creates transformative handheld point-of-care ultrasound solutions by infusing premium ultrasound performance with industry-leading AI educational tools providing more clinicians with increased information faster. Visit our website at https://www.echonous.com/ Explore a directory of our most popular content https://linktr.ee/echonous.kosmos

EDDA Technology, Inc. is an innovative leader in the rapidly growing field of imaging-guided cancer treatment. By adopting a fully quantitative, real-time interactive approach to imaging analysis, simulation and guidance, our next generation computer-assisted radiology and surgery solutions go well beyond advanced 3D image visualization. The award-winning IQQA® platform supports a patient-specific, disease-targeted, and multi-disciplinary approach to cancer treatment. With exceptional ease-of-use and clinical versatility, it facilitates efficiency and precision in treatment planning, guidance, monitoring, and follow-up. The IQQA® platform provides targeted solutions to assist physicians in advanced clinical applications including: fast 3D quantitative analysis and visualization, highly automated volumetric organ/lesion segmentation & quantification, pre– & post–operative assessment, treatment planning & simulation, procedural guidance and monitoring, and Computer-Aided Detection (CAD).

Eden Bio uses machine learning to improve protein yield, saving companies time and money, and helping them get their proteins to market faster.

Edeniq, Inc. is a leading biotechnology company specializing in innovative, analytical solutions for the biofuels industry. With a focus on the analysis of fiber and cellulosic ethanol, Edeniq helps its customers quantify and qualify increased yield value and reduced carbon intensity, and optimize plant operations. Founded in 2008, Edeniq’s experienced team and strong customer focus have established the company as the top analytical testing service provider for ethanol producers across North America. Learn more at www.edeniq.com.

Founded in 2006, eHealth Technologies is the industry-leading provider of clinically informed referral services. We serve more than half of the nationÕs top 100 hospitals, including 16 of the top 20 U.S. News & World Report Honor Roll Hospitals for 2016-2017, and leading health information exchanges (HIEs) across the United States. The companyÕs eHealth Connect¨ solution enhances patient and physician satisfaction by streamlining referrals and intelligently aggregating patientsÕ clinical records. This assures physicians have the right healthcare information to care for their patients, right when they need it. As a critical adjunct to HIEs, eHealth Connect¨ Image Exchange enables the automated access to all types of medical images in the context of the aggregated patient record, in full diagnostic quality, and supports the ability of providers to meet Meaningful Use Stage 2 requirements.

Eigen Therapeutics is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of 'priming' therapies that improve efficacy while reducing the toxicity of small molecule therapies.

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

Eleven Therapeutics is a biotechnology company leading the AI revolution in nucleic acid therapeutics. They harness the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process.

Elnora AI is revolutionizing drug discovery by harnessing the power of AI and the academic research community. This approach accelerates the R&D process, makes it faster, more cost-effective, and more reliable by avoiding repeated mistakes.

We are a skincare startup founded in 2018 in San Francisco. We combat the rise of skin conditions and sensitive skin by building a world in which beauty and science work together to produce optimal health. We develop clean, science-backed products that respect our skin's natural ecosystem. Discover our B2B microbiome tech platform @hellobiome. Our founder, Elsa Jungman, has a Ph.D. with strong expertise in dermatology, microbiome and clean beauty. She is a UCSF, L'Oréal and AOBiome alumna.

Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.

Recognized as the 'Most Innovative Biotech Company, 2024', by Fast Company! Even today Early R&D, Precision Diagnostics and Translational Biomarker teams spend about 80% of their time wrangling data. Elucidata's mission is to empower scientists in the life sciences field by reclaiming every valuable hour for their research endeavors. Elucidata’s data harmonization platform - Polly, helps research teams make multi-modal biomedical data Machine Learning ready. Each dataset on Polly is processed consistently using pipelines of your choice, is custom curated with granular annotations and undergoes robust QA/QC checks to ensure highest data quality standards. Polly transforms multi-modal and multi-source biomedical data (Omics, Assay, Real World Data, Clinical & EHR Data, and CRO data) into a Unified Data Model. With our 10X faster LLM-powered curation and human-in-the-loop model to achieve 99.99% accuracy, we are fast-tracking time to analysis. Today, Polly is facilitating use case like patient stratification, biomarker discovery, target ID & validation, data management, and development of clinical and commercial pipelines across Pfizer, Janssen Pharmaceuticals, NextGen Jane and IMBDx and over 35 premier biopharma companies and research labs. Head-quarted in San Francisco, we are a 120+ multi-disciplinary team of experts based across the US and India. In September 2022, we raised $16 million in our Series A round led by Eight Roads and F-Prime along with our existing investors Hyperplane and IvyCap. Write to us at info@elucidata.io for queries To talk to us, visit: https://www.elucidata.io/book-a-meeting For more information, visit: https://www.elucidata.io/ Visit Our Offices - San Francisco Head Quarters: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Boston Office: 625 Massachusetts Avenue Cambridge, MA 02139 R&D Hubs, India - Delhi and Bangalore

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.

CompuGroup Medical is a leading provider of healthy solutions for healthy patients and healthy providers. We offer integrated electronic health records, practice management software, revenue cycle management solutions, and credentialing services for physician practices and enterprises. Founded by physicians, the company is an industry leader for usable, connected software that enables physician productivity and a superior clinical experience. eMDs software has received top rankings in physician and industry surveys including those conducted by the American Academy of Family Physicians’ Family Practice Management, AmericanEHR™ Partners, MedScape®, and Black Book®. For more information, please visit http://www.emds.com.

Emerald Clinical is a global clinical research organization (CRO) that specializes in end-to-end clinical trial management. Operating in over 70 countries, the company has completed more than 600 clinical trials, with a strong focus on Oncology and Cardio-Renal-Metabolic research. With over 20 years of experience, Emerald Clinical aims to mitigate clinical development risks through localized solutions and scientific leadership. The company offers comprehensive services, including protocol design, site selection, and regulatory compliance. It emphasizes predictable trial delivery and inclusive trial design, ensuring diverse patient populations are represented in research outcomes. Emerald Clinical serves over 100 biotech companies and six of the top ten pharmaceutical firms, leveraging its expertise and reputation for reliability. The leadership team, supported by an advisory committee of active researchers and clinicians, is dedicated to advancing clinical research with transparency and innovation.

Emerald Cloud Lab® (ECL®) provides researchers from various disciplines with access to state-of-the-art scientific labs from anywhere on earth, 24 hours a day, 365 days per year. With ECL researchers utilize a single software interface to securely design, run, and analyze experiments, allowing researchers to spend more time designing protocols and analyzing data, and less time on mundane time-intensive activities in the lab. With ECL every researcher utilizing the platform becomes more productive, and more efficient while reducing operational costs and the impact on the environment.

Empire Genomics is a leading biotechnology company focused on the development of advanced molecular diagnostics and genomic products. Our mission is to accelerate precision medicine by providing tools that empower researchers, clinicians, and pharmaceutical companies to better understand, diagnose, and treat complex diseases, particularly in oncology. We offer an extensive portfolio of FISH (Fluorescence In Situ Hybridization) probes, ancillary reagents, and custom assay development services. These products are essential for detecting genetic abnormalities, such as gene amplifications, deletions, and rearrangements, critical for diagnosing and monitoring various cancers and genetic disorders. Committed to quality and innovation, our products are rigorously tested to meet the highest industry standards, ensuring reliable results. Selling products globally through a network of distributors, Empire Genomics continues to advance personalized medicine, enabling healthcare providers worldwide to deliver more targeted and effective treatments to patients.

Enamine has developed the world's largest reputable collection of chemical compounds, carefully designed and produced for Life Science industries. Stock collections: 4M+ screening compounds, 250k+ fragments, 300k+ building blocks. Comprehensive services in lead discovery and optimization are available including integrated biomolecular and ADME/TOX screening, all on-site.

At EnClear Therapies, we are combining Bioscience & Med-tech expertise to develop solutions that improve and extend the lives of patients with CNS disease. The team at EnClear is developing systems and medical interventions that Access, Recirculate & Modify CSF for: › Targeted removal of toxicity from CSF correlated to neurodegenerative disease progression. › Continuous localized delivery of therapeutics & monitoring of CSF to ensure effective and personalized therapy.

Engimmune is an immunotherapy company utilising cutting-edge methods for the development of T-cell receptor (TCR)-based immunotherapies including T cell therapies and biologics. By applying our unique protein engineering toolbox we have established and continue to develop proprietary high-throughput technology platforms enabling the discovery of highly potent and safe TCR-based cell therapies and biotherapeutics, thus covering the entire TCR discovery value chain. Operating as a platform technology and product development company, our vision is to become a globally leading provider of best-in-class TCR-based therapeutics for the treatment of serious human diseases with high unmet medical need, with a particular focus on oncology. Engimmune is based in a brand new science park in Allschwill, Basel in Switzerland

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

ENPICOM is an innovative bioinformatics software engineering company committed to accelerating biologics discovery and development through cutting-edge bioinformatics solutions. With a deep understanding of biology, software engineering, and AI, ENPICOM delivers innovative tools that empower scientists to make groundbreaking discoveries faster and more accurately. For more information visit enpicom.com.

Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

Enthought specializes in digital transformation of science-driven companies in the materials science, chemistry, semiconductor, life science, and energy industries. In today's competitive global business environment, it's imperative that R&D organizations move from the traditional human-centric model to a digital, compute-centric infrastructure. Enthought is expert in this transition. We have been providing technical consultation and implementation services for scientific R&D for over 20 years.

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

Enzymit is setting a new paradigm for bioproduction through the design and creation of novel enzymes that streamline production processes, reduce costs and promote sustainability. Through cell-free, synthetic biology bioproduction, we aim to make faster, simpler, and more cost-effective than fermentation-based methods, meeting the demands of a constantly evolving world. Established in 2020 by experts in computational science, Enzymit uses deep learning algorithms and high-throughput testing methods to develop novel enzymes for various applications such as fine chemical manufacturing, foodtech, health, biodefense and more. Our team collaborates with global manufacturers across multiple industries, driving both expansion and market impact.

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases.

At Epistemic AI we are building the next generation of tools to accelerate biomedical research with AI and NLP. We are a group of senior scientists and engineers from the likes of Google, New York University, Stanford and more. We are dedicated to enabling advances in biomedical research and practice with AI and NLP.

Epitel is a digital health company modernizing brain health solutions to improve seizure monitoring and detection.

Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn’t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.

Essenlix Corporation is a fast-growing startup company in Princeton that develops a new easy-to-use, ultrasensitive, fast, assay platform for life science, diagnostics, and personal health.

Etcembly’s vision is to decode immune repertoires for health and disease. The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally. We are pushing the frontiers to explore the intersection between immunology and machine learning.

A specialist in computational drug discovery with a focus on developing RNA interference (“RNAi”) therapeutics

Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.

埃格林医药是一家高速发展的国际化生物医药公司，以“关注临床迫切需求，惠及全球广大患者”为使命，致力于在全球范围内的临床研发与商业化推广

Everlum Bio is pioneering a novel approach to drug development for rare diseases. As opposed to working on a single disease we are doing "Drug Development as a Service". We are relentlessly focused on innovating the drug development process. Ultimately we believe this approach will usher in a personalized/precision medicine revolution.

Every Cure is a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

Evia Bio™ is a life science innovation company enabling the growing cell therapy market. We provide new non-DMSO cryopreservation solutions developed by world-leading cryobiologist, Allison Hubel, PhD. We partner with cell therapy companies looking to advance their products to clinical trials and commercialization. Our solutions unlock the full potential of emerging life-saving therapies through the use of all-natural organic compounds to protect the integrity of cells during cryopreservation and patient safety at the point of care. Please visit www.eviabio.com.

Evidation creates new ways to measure and improve health in everyday life—making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe.

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com

EvolutionaryScale is a biotech startup focused on AI research in the field of biology. The company has developed a database of over 2 billion protein sequences to train its AI model, offering technology that can provide insights into biological processes. EvolutionaryScale has raised significant funding, including a $142 million seed round, and is known for its ESM3 Generative AI Model for biology.

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs.

Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company's proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies. We know that people are our greatest asset and we are rapidly building a rock-star team of talent. Our people are driven by the mission, inspired by the vision of the future, and are committed to living our core values (integrity, openness, teamwork, exploration, and kindness) that connect us to our work and to one another. What We Value Our core values represent what we stand for as a team. This is what we believe in. Everyday, we strive to align our behaviors to these core values in everything we do. Integrity – Our thoughts and actions are true to science and to people. We do the right thing. Openness – We recognize and respect our differences – and embrace learning from them. Teamwork – We are team players who trust and respect each other. Exploration – We are explorers, putting curiosity into action. Kindness – We are kind whenever possible – and we believe it's always possible.

Discover how Excelra, a leader in biopharma data and analytics, uniquely blends scientific understanding with technological expertise. This dual mastery empowers innovative drug discovery and development, transforming research data into actionable insights for groundbreaking discovery. 𝗘𝗺𝗽𝗼𝘄𝗲𝗿𝗶𝗻𝗴 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 Excelra's interdisciplinary approach combines life science expertise with cutting-edge technology. This leads to confident, data-centric decisions, simplifying your data-driven drug discovery journey and accelerating your research. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 At Excelra, collaboration is key. By co-creating solutions, we amplify your team's capabilities, blending scientific insight and technological acumen for more valuable discoveries and greater project control. 𝗙𝗿𝗼𝗺 𝗖𝗵𝗮𝗼𝘀 𝘁𝗼 𝗖𝗹𝗮𝗿𝗶𝘁𝘆: 𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗗𝗮𝘁𝗮 We navigate the complexities of drug discovery, enhancing your success by structuring chaotic data into actionable insights, leveraging our scientific and technological prowess. 𝗖𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗬𝗼𝘂𝗿 𝗚𝗼𝗮𝗹𝘀 Your goals of faster drug development and better patient outcomes are central to our mission. Committed to delivering insights and tangible progress, we ensure each data point contributes to your innovation journey, helping you 'Excelrate' towards success. 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿 Join us in redefining drug development. Our services span across the life science value chain, from molecule to market. At Excelra, each data point is a step towards a healthier future. Discover how partnering with us can 'Excelrate' your healthcare innovations.

Exegenesis Bio is a clinical stage global gene therapy company with operations in Philadelphia, Boston and China. The company’s innovative gene therapy pipeline is based on proprietary capsids, promoters and unique protein engineering designs. Two programs have advanced to the clinical stage: (1) Type I Spinal Muscular Atrophy (SMA) AAV gene therapy in China (2) neurovascular AMD (wet AMD) rAAV gene therapy in USA The company has built state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids. Exegenesis Bio has raised over $150 M since inception in 2019 and currently employs over 200 scientific and operations staff worldwide. Website: https://www.exegenesisbio.com/ Contacts: Company Information: Contact@ExegenesisBio.com Business Development: BD@ExegenesisBio.com Careers: Careers@ExegenesisBio.com

Getting genetic syntax right. With precise use of genetic grammar in transgenic design, ExpressionEdits unlocks the capacity to make proteins previously beyond reach.

We are a specialty CDMO for LV vector manufacture & use. Our three platforms: Expression Cassette Optimization (ECO), LentET (3rd gen system), & LentET Express (cGMP mfg.) enable GMP LV manufacture 10 months from sequence submittal. ECO increases expression up to 8 fold. LentET plasmids are ECO optimized, have improved safety, produce potent LVs & may be available royalty/licensing free depending upon the specifics. With full CMC & regulatory support, Expression is your preferred CDMO of choice.

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

At Eyam, our mission is to bring “Next Generation” vaccine and therapeutic technologies to market to solve today's health care needs.

Eybna is a technology company and a leading terpene manufacturer. Eybna's forward-thinking R&D center aims to contribute to the health of mankind by utilizing the therapeutic benefits of cannabis phytochemicals, with a focus on terpenes. Eybna's strong and profound partnership with academia and leading industry partners, allows the company to constantly integrate advanced research in the process of product development, transforming valuable scientific knowledge into easily applicable products, for the immediate benefit of people worldwide. Eybna has an R&D center based in Israel, and a US office based in California.

Fable Therapeutics Inc. was founded with a conviction to revolutionize drug discovery through the purposeful integration of AI techniques. ‍ Our cross-functional team of ML scientists and drug hunters collaborate to design novel medicines with expanded therapeutic potential. ‍ With this passion and vision, we’re designing the future of drug discovery.

FAR Biotech is a preclinical, computational drug discovery company that focuses on hard-to-drug targets that have high scientific and commercial value. Founded by Dr Martin Martinov after 25 years in academia and industry -- and named after the Bulgarian word “far” that translates into “lighthouse” or “beacon” -- FAR seeks to shine a light on drug discovery in areas of high unmet clinical need. FAR's proprietary technology can more rapidly identify novel, structurally diverse, optimized, lead molecules that other approaches would not look for, let alone find. The key differentiator is FAR's complete and rigorous quantum mechanical representation of drug-target interactions -- which embeds the advantages of quantum similarity and multi-property optimization for hit and lead identification -- augmented by AI / machine learning & big data. FAR's quantum biomodelling platform has been validated preclinically across a number of therapeutic areas, including neurodegeneration, oncology and infectious diseases.

Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.

FDNA uses facial analysis, deep learning and artificial intelligence to transform big data into actionable genomic intelligence to improve diagnostics and therapeutics.

Fibronostics is a healthcare technology company providing algorithm-based solutions in a variety of diagnostic testing areas, focusing on assessing liver disease existence/progression, but also other chronic areas such as coronary heart disease, stroke, diabetes, and obstructive sleep apnea. Fibronostics'​ LIVERFASt products provide early detection and monitoring for patients with NAFLD & NASH when a diagnosis is often missed due to limited screening with low-sensitivity tools. The current standard for diagnosis is risky and costly with mounting evidence calling for an efficacious and cost-effective non-invasive diagnostic tool. Fibronostics'​ HealthFACTR tool employes technology to predict risk, providing results for risks of coronary heart disease, stroke, diabetes and fatty liver disease. HealthFACTR enables action-oriented recommendations which allow healthcare professions to determine patients'​ risk levels and drive better patient care.

We are a Bioinformatics Provider with clients in the UK, Europe and America. With over 15 years of experience in supporting scientists, researchers and bioinformaticians in data analysis, we have an extensive experience in handling all types of datasets for drug discovery & development, diagnostics, agricultural research, veterinary medicine and applied research across all species. Our specialised team of bioinformaticians, statisticians and biologists are able to analyse and interpret any genomic, transcriptomic, proteomic & metabolomic data, independent of the platform used. We are very well appreciated among our clients for our proprietary computer solutions that allow parallelisation of large datasets analysis that saves processing time and avoids the complications that arise when analysing data in batches. Results of the analysis are always presented in a secure web report that is complete with all references and results. Types of services offered by FIOS: ● Technology/Platform Selection ● Study Design & Biostatistics ● Data QC and Pre-processing ● Biomarker Identification & Validation ● Genomic Signature Development ● Data Visualisation ● Preclinical Safety & Toxicology Investigations ● Clinical Trial Analysis ● Drug Repurposing For more info, get in touch: https://www.fiosgenomics.com/contact-us/ Twitter: @fiosgenomics Facebook: https://www.facebook.com/fiosgenomics/ Office Phone Number: +44 (0)131 322 3770 Office Address: Fios Genomics Ltd, BioCube 1, 13 Little France Road, Edinburgh BioQuarter, Edinburgh, EH16 4UX

Welcome to the future of neurological assessments with Firefly Neuroscience’s FDA-cleared Brain Network Analytics (BNA™). Utilizing ADVANCED AI and an extensive proprietary EEG database, BNA™ combines the automatic analysis of Event-Related Potentials (ERPs), spectral EEG, and behavioral performance data for a comprehensive and objective data-driven brain health evaluation.

For patients whose cancer has returned, First Ascent Biomedical provides new ways to fight by combining functional drug testing, genomics, and artificial intelligence to design an individualized treatment plan in a week for each patient. Our technology rapidly grows tumor bulk, more importantly chemo-resistant cells enabling the testing 100s of FDA-approved drugs to measure the cellular response of both cell populations. This is the key dataset for the AI engine, supported by genomics data to identify every cancer weakness and identify which drugs work.

Flagship Biosciences is a leader in spatial biology and biomarker analysis, bringing innovative approaches to clinical research and drug development. The company delivers the most accurate and informative data available in the field of spatial biology and biomarker services.

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

Flomics is developing novel blood-based diagnostic tools for a broad range of complex diseases. Our proprietary technology accurately identifies pattern changes in the circulating long RNA molecules of patients. With deep learning algorithms we identify RNA changes associated with disease states in a faster, cheaper and non-invasive way.

FluoroFinder is developing innovative cloud-based research tools for the search of fluorescent reagents and the design of medical experiments: accelerating the research initiatives aimed at curing Cancer, HIV, Multiple Sclerosis, in addition to other infectious diseases. Simplifying the complexity of managing the life-cycle of reagent selection, FluoroFinder's technology solutions offers unparalleled support and resources to core facilities and labs. Members receive additional benefits and support to drive efficiencies and resource savings. FluoroFinder's technologies save thousands of days - and millions of dollars - for research institutions every year! Please contact us at info@fluorofinder.com to request a demo.

Forever Oceans is pioneering a new way to produce delicious, natural seafood that's good for people and the planet. We combine our expertise in off-shore aquaculture with unique innovations to ocean-raise fish that are always delicious, healthy, and sustainable.

Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

Form empowers scientists to harness the data, computing power and collaboration that drive how today's breakthroughs are made.

Fraunhofer is EuropeÕs largest application-oriented research organization. Our research efforts are geared entirely to peopleÕs needs: health, security, communication, energy and the environment. As a result, the work undertaken by our researchers and developers has a significant impact on peopleÕs lives. We are creative. We shape technology. We design products. We improve methods and techniques. We open up new vistas. In short, we forge the future.

Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.

Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.

Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people.

We are building the largest longitudinal cohort in the Americas to power precision health at scale for all. Our goal is to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. We are focused on Latin America and our diaspora populations throughout the world including founder populations in the Americas, those who identify as Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander as well as people who self identify as belonging to two or more of these groups. Core to our mission is building trust with the communities we serve and long term partnerships with communities, researchers, clinicians, and most of all patients and their families. This is your biobank and for the benefit of all. If we build it, we can decide how the data are used. And no one is going to do it for us, so let’s roll up our sleeves and “time to build.” Join us! Este biobanco es tuyo y para todo el continente porque si lo construimos juntos podemos decidir cómo se usan los datos y con que fines. Nadie lo va a hacer por nosotros así que bienvenido a nuestro esfuerzo. Unete!

There are more and more humans. More and more of them need surgery. Orthopedics especially is driven primarily by age and weight so... yeah. It's going to be impossible to train as many surgeons, let alone good and experienced ones, as the world needs. So what do we do? Let people die of a fractured hip? We believe technology holds part of the answer. We believe the success or failure of a surgical intervention shouldn't be a direct result of the surgeon's state of mind. We believe it's possible to create tools that will improve both patient outcome and surgeon experience. We believe it's unacceptable to live in a world where *5 billion* people have no access to surgery whatsoever. We develop advanced robotics technologies for orthopedic surgeons. So that more people have access to life-changing orthopedic surgeries, safely and affordably. Freedom starts with movement. And we believe in what we do. Supported by A-Level entrepreneurs and innovators such as Bruno Maisonnier (Founder of Aldebaran Robotics, Founder & CEO AnotherBrain) and world-class orthopedic surgeons, we work hard to change the status quo in surgery. We are incubated at one of Europe's best life science incubator, Paris Biotech Santé (ever heard of DNAScript, Therapenacea and Therapixel ? They are here too). We have raised significant seed money. We have gathered a world-class team. We're all in. We're still hiring.

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach, which accelerates therapeutic development with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid novel target identification/verification, and drug discovery/development. GATC Health envisions the future of medicine now, where disease is reversed safely so everone can live their best lives.

GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church's lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

Geisinger Medical Laboratories, a medical reference laboratory in Pennslyvania (PA). Dedicated to caring, laboratory excellence, patient safety, quality assurance, and service excellence.

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.

Founded in 1997, Genedata delivers enterprise solutions to enable Biopharma R&D globally to discover, develop, and manufacture innovative biotherapeutics faster and more efficiently. Genedata combines computational, scientific, and technical expertise with extensive biopharma R&D domain knowledge to deliver user-friendly solutions that are scalable, open, and aligned with industry processes. Today, most of the leading pharmaceutical, biotechnology, and agrichemical companies, as well as innovative life science research institutions rely on Genedata. Genedata is proud to be part of Danaher. Danaher’s science and technology leadership puts Genedata’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Genemod helps scientists maximize productivity in their research to drive the next generation of medicines. Genemod helps solve problems of data sharing and data archiving for research labs by providing inventory, experiment management, applications, and data, all in one collaborative workspace.

GenePlanet is the leading European provider of preventive genetic tests, specialising in NIPT, cancer screening, and lifestyle DNA tests.   With over 15 years of experience in the market, GenePlanet collaborates with over 1000 medical centres, doctors, and insurance companies to provide top-quality tests based on the latest scientific discoveries. The company’s tests are designed to empower individuals to take control of their and their baby’s health, as well as assist doctors with therapeutic procedures. GenePlanet adheres to the highest standards of quality and is constantly striving for new discoveries through its research and development efforts. With a presence in more than 35 countries worldwide and over 100,000 satisfied customers, GenePlanet has been recognised as one of the 1000 fastest-growing companies in the EU by the Financial Times and one of the Top 35 EU Unicorns by the European Commission.

The company offers products and services in:advanced probiotics and feed additivesgenetically engineered probioticsassays and screens of probiotics, andcustom probiotic fermentation.

Generate:Biomedicines is a new kind of therapeutics company—existing at the intersection of machine learning, biological engineering, and medicine—pioneering generative biology to create breakthrough medicines. Through The Generate Platform, we are able to expand the breadth of technical possibilities in order to fundamentally change the way medicines are made.

Geneseeq is a research-driven company providing cutting-edge next-generation sequencing (NGS) technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type-specific gene panels for all sample types to help match a patient to the optimal treatment, including targeted therapy and immunotherapy for solid tumors and blood cancers. Additionally, we develop cutting-edge technologies and kits for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Our testing services are conducted in our CAP/CLIA/ISO15189-accredited laboratory, where we manufacture IVD and RUO testing kits for in-house solutions. With a global reach, our headquarters are located in both Canada and China. Our products and services are well-established and ordered by over 8,000 long-term oncologist partners across 12+ countries and regions. We are engaged in 2,200+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We work closely with our partners to address their specific needs, maintaining a relentless focus on quality and efficiency.

Genesis Drug Discovery and Development (GD3), a member of Genesis Global Group, is a contract research organization focused on providing services to support preclinical drug development programs from discovery to candidate selection. Our diversified portfolio of services covers all the areas of preclinical drug discovery/development including Discovery Biology, Chemistry, DMPK/in-vivo pharmacology and Toxicology. The portfolio spans a wide range of therapeutic areas include oncology, ocular, inflammation, metabolic diseases, ​and microbiome.

Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020). Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.

We are a global player in life-science R&D informatics, providing customers with cutting-edge multi-omics data management and integration software. We develop innovative off-the-shelf and custom solutions for clients in pharma, biotech, agriscience, consumer goods, and research centers. Omics Data Manager (ODM), our flagship product, helps organisations create a FAIR catalogue of multi-omics investigations (studies, samples, omics data), with powerful tools for curating rich and standardised metadata in bulk, as well as optimised RESTful APIs for scalable cross-study, cross-omics integrative search. We complement this product with a complete range of professional services including technology consulting, product implementation, managed service and co-development models. We are based in Cambridge, United Kingdom.

Created in 1990 and funded by AFM-TELETHON, Genethon, a pioneer in deciphering the human genome and identifying the genes associated with genetic diseases is today fully dedicated to the design and development of gene therapy treatments for rare diseases. At Genethon more than 180 scientists, clinicians and engineers specialized in gene therapy drug development, from research to the clinic, have joined forces in order to provide these innovative treatments to patients affected with rare disorders. These treatments also pave the way for new therapeutic approaches for frequent disorders.

NeuroKaire by Genetika+ a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. NeuroKaire uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Geneyx offers best-in-class practices harnessing #geneticdata available to guide digital insights for rare and #germline disorders and diseases. We aim to enrich disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and #pharmaceutical organizations.

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas: five programs in acute on chronic liver failure (ACLF) are in clinical stages (Phase 2) and pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; a Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA). GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital.

Genialis is a precision oncology company based in Houston, USA, founded in 2013. The company is dedicated to advancing drug programs from the lab to the clinic through its data science platform. Genialis aims to enhance cancer treatment effectiveness by utilizing advanced AI models and deep biological expertise to provide insights into patient responses and drug mechanisms. The company offers several key services, including therapeutic intelligence and biomarker discovery, which help pharmaceutical companies identify therapeutic targets and understand disease mechanisms. Genialis also provides digital disease models that uncover drug targets and biomarkers related to treatment efficacy and outcomes. Additionally, its precision medicine solutions leverage diverse datasets and AI to improve patient stratification and clinical success. Genialis primarily serves clients in the pharmaceutical industry, including biopharmaceutical firms, diagnostics companies, and clinical researchers, focusing on areas such as oncology, neurodegenerative disorders, and immunology.

GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient's genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients' health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.

At Genix Cure, we're on a mission to redefine well-being through the power of nature. We craft innovative, natural remedies that promote health and vitality, utilizing the genesis of nature's ingredients. Our commitment to authenticity and purity ensures that our products can be consumed daily, fostering wellness without compromise. Join us on our journey to a healthier, more rejuvenated life, where we believe that the path to well-being begins with nature's own genesis.

Gennova Biopharmaceuticals Ltd. is a biotechnology company based in Pune, Maharashtra, India. The company specializes in the research, development, production, and commercialization of biotherapeutics and vaccines aimed at treating life-threatening diseases in areas such as cardiovascular, neurology, nephrology, and oncology. Gennova employs advanced recombinant DNA technologies and innovative bio-manufacturing practices to create effective biotherapeutic solutions. The company utilizes various expression platforms, including bacterial, mammalian, and yeast-based systems, to produce its recombinant products. Gennova has successfully commercialized seven products, including Tenectase, a biosimilar for treating Acute Ischemic Stroke, and HAMSYL, a treatment for acute lymphoblastic lymphoma offered at a lower price point for better accessibility. With a strong focus on research and development, Gennova is recognized as a preferred partner in the vaccine sector for research and cGMP manufacturing. The company employs around 598 people and has reported a revenue of $2.8 million, positioning itself as a notable player in the Indian biotechnology landscape.

GenomeKey enables targeted Sepsis treatment in hours, rather than days. This is important because Sepsis now kills more people than cancer. It can hit anyone, of any age, and kills within hours. A patient admitted to a hospital today, they wait 3 days before the doctor knows which antibiotic will fight the infection. We use cutting edge machine learning and DNA sequencing to bring 3 days down to just a few hours, with the only affordable test that provides a result for every patient. This saves lives, saves money, and saves our last antibiotics for when we really need them.

Genomenon is a leading genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development. The company’s solutions include software, data, and services. Genomenon offers advanced genomic software solutions designed to streamline and enhance genetic research and clinical decision-making. Our flagship product, the Mastermind® Genomic Intelligence Platform, provides comprehensive genomic data integration and analysis, offering researchers and clinicians a powerful tool to interpret genetic variants and their clinical relevance. Complementing this is the Clinical Knowledgebase (CKB), which focuses specifically on the landscape of somatic mutations, offering curated, actionable insights to support oncology research and personalized cancer treatment. Together, these platforms aim to accelerate discoveries and improve patient outcomes through sophisticated data analysis and knowledge integration.

GenomOncology enables real-time clinical decision-making at the point-of-care for Molecular Pathologists, Clinical Oncologists and Cancer Informaticists in their research of cancer treatments and therapies for cancer patients.

A One-Stop-Shop Gene to Antibody Partner Genovac is a contract research and manufacturing organization committed to positioning our clients for the successful development of new transformative drugs and diagnostics. Genovac specializes in antibody discovery and production against challenging targets. Our unique combination of genetic immunization, multiple host species, multiple single B cell platforms, and state-of-the-art production facilities enables us to serve as your one-stop-shop Gene to Antibody partner.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 200,000 customers from over 100+ countries and regions worldwide have used GenScript's premier, convenient, and reliable products and services. GenScript has over 6,900 employees globally, with about 10% R&D personnel. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 300 patents and about 900 patent applications. As of December 31, 2023, GenScript's products and services have been cited by 87,745 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

Gense Technologies is a healthtech startup offering an affordable and portable health screening device for preventive care and chronic disease monitoring at elderly services, clinics and home care, specifically for liver, lungs, kidney and more. The company has secured investments from Alibaba Entrepreneurs Fund, Gobi Partners, HKUST, Cyberport, and HKSAR Government’s ITVF. The proprietary technology is developed by a team of PhDs and top talents in Hong Kong. Gense is also the Jumpstarter Global Competition, the Grand Award at Hong Kong ICT Startup Awards, and Forbes 100 to Watch. Gense is collaborating with healthcare providers in Hong Kong and globally to set up local deployment pipeline, including primary healthcare, hospital network, clinic chains, elderly service, and multinational conglomerates.

Based in Sudbury, MA., Gentuity is a commercial-stage medical technology firm dedicated to developing next-generation intravascular imaging devices capitalizing on today's best-in-class technologies. Gentuity was founded on the principles of advancing patient care, improving outcomes, and expanding the utility of intravascular procedural guidance tools in the realm of cardiovascular disease. The Gentuity High-Frequency OCT Imaging System is the first commercially available OCT imaging system to deliver Total Vessel Imaging with the first 1.8F micro-imaging catheter. Gentuity and its' next-generation platform are paving the way for transformation in the intravascular imaging world. Designed to support the growing needs of the imaging industry, the platform incorporates AI and machine learning with the intention of creating "collaborative intelligence" to enhance ease of use and procedural success.

We are a preclinical stage AI drug discovery company with a mission to eliminate age-related diseases We use AI to build clinically relevant disease phenotypes in real-world human data and identify diseases with shared biology. Then WES-enabled genetic study on these phenotypes allows us to discover novel targets applicable to several indications at once. You can find our publications here: https://gero.ai/publications

Gestalt transforms pathology through an intelligent, configurable, and vendor-neutral, AI-driven, digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences. This platform consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing their invaluable experience where it matters most. *Research Use Only (RUO) unless following CAP guidelines for LDT.

Gilgamesh is a clinical-stage biotech whose vision is to reshape how mental illnesses are treated by shifting away from symptom management to a focus on rapid-acting and durable therapies targeting the fundamental drivers of disease. We do this by designing best-in-class new chemical entities (NCEs) acting through proven mechanisms, which are optimized for safety, efficacy, and patient access

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Our mission is to use visionary science and technology to overcome major unsolved diseases.

Glytec's industry leading SaaS platform, trusted by 350+ hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing readmissions, and streamlining workflows while delivering a 6-8x ROI. The first-ever FDA-cleared cloud-based insulin management software is EMR-integrated, easy to set up, and validated by 106 patents and over 100 publications. The Glytec Glucommander® solution, with clinical decision support, workflow alerts, patient monitoring, at-risk patient identification, and AI-driven analytics, is supported by a mission-driven team dedicated to helping healthcare leaders, clinicians and patients promote health equity and improve diabetes outcomes from hospital to home. We are on a mission, join us. For more information, follow Glytec on X (@Glytec) or visit www.Glytec.com.

GNS Healthcare is a healthcare analytics company that specializes in precision medicine and biomedical research through advanced health data analysis.

❌❓ THE CHALLENGE: Glycans hide the tumor in disguise. ➡ Typical cancer-specific Tumor Glycocodes render the tumor invisible to the immune system, they stay ‘cold’. Intelligently, glycans from that Tumor Glycocode are not present on neighbouring healthy tissue, rendering it a perfect target for eradication & potential use as biomarker for patient selection and treatment response. ➡ So far, efforts to break that code for therapeutic benefits have been unsuccessful. One reason for this is the dynamic shape & motion of glycans, and the inability to manufacture them ex vivo. ⭕❗ THE SOLUTION: Conjugated Glycopeptides. Gnubiotics’ proprietary technology conjugates O-glycans with short protein parts - peptides - ex vivo to form novel glycopeptides that are druggable targets amenable to mass production. 🔜 Breaking the Tumor Glycocode. Since 2019, multiple preclinical models have demonstrated proof of concept for the lead compound GNU101 to be orally bioavailable, resisting degradation, and surviving enzyme proteolysis. The preclinical body of evidence has demonstrated proof-of-concept that the GENESIS platform based glycopeptides are able to turn 'cold' into 'hot' tumors, breaking through I/O resistance and inducing tumor cell killing. 💡 THE TEAM: We are a highly specialized team of Founders, Scientists and Entrepreneurs pursuing the transition from a large basis of preclinical evidence into IND-readiness and the clinics with First-in-human clinical phase 1 study for colorectal cancer patients in 2024/2025. 📥 Curious to learn more? Check out our new website and contacts 🌐 https://gnubiotics.com/

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

Process, analyze, and annotate genomics and biomedical data at scale using containerized workflows.

Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of patients are left without adequate treatment options - and AI trained with complex disease data can solve this.

Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision of Disruptive Revolution of Biologics Development. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, and in industries involving bioprocessing, e.g., synthetic biology, IVD and CGT. Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States. GBB has launched multiple proprietary AI biotech platforms; AlfaCell, an AI-enabled site-specific integration cell line development platform that resolves multiple developmental bottlenecks, including unpredictable cell line stability and labor-intensive screening during CLD. Additionally, the AlfaMedX platform is an AI-enabled cell culture media development platform, responsible for creating over 50 unique cell culture media that outperform commercially available CHO cell culture media. GBB has secured 40+ patent applications, related to AI-enabled biological platform. Recognizing the potential of these platforms, GBB has formed partnerships with over 20 leading domestic and international companies.

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, let's transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

Based on world-leading technology, we are developing a unique ultrasound helmet that is as portable as it is precise. Our first disease target: Alzheimer’s disease.

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Automate and scale your participant recruitment and engagement with the Grove AI Assistant and PRM™. Our AI assistant is available 24/7 and adapts to every trial, ensuring the right participants are connected to the best clinical trials.

Grove Biopharma is a preclinical biotechnology startup, pioneering the discovery and development of a new class of synthetic biologic drug modality to access challenging drug targets. Our Precision-Linked Proteomimetic therapeutic platform has the potential to address significant unmet medical needs in oncology, neurodegenerative disease, and other rare diseases.

In April 2024, Deloitte acquired substantially all of the assets of Gryphon Scientific LLC. The team, comprised of life scientists and health researchers who apply rigorous scientific analysis to problems of global health and homeland security, is now part of the Deloitte GPS Federal Health sector. Our projects drive policy changes in security, preparedness, and science policy at the highest levels of US government.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Guided is a Georgia-based medical technology company that develops and commercializes non-invasive medical devices for early detection of cancer.

At Harbinger Health, our mission is to change the cancer paradigm by taking a proactive approach to cancer detection and prevention. We envision a future where cancer is no longer a life-altering event, but a routine health problem that can be addressed with early intervention. To achieve this, we have developed proprietary solutions for cancer pre-emption, starting with blood-based tests that can detect cancer before it even becomes visible. By identifying biological programs that are the root cause of cancer, we can enable early-stage and pre-disease identification, leading to truly personalized and effective cancer care for everyone. With Harbinger Health leading the way, we believe that a cancer-free future is not only possible but within reach, for everyone.

Harter Secrest & Emery LLP is a full-service business law firm providing legal services to clients ranging from individuals and family-owned businesses to Fortune 100 companies and major regional institutions. With offices in Buffalo, Rochester, Albany, Corning, and New York City, New York, the firm is a recognized leader in litigation, corporate, employee benefits, environmental and land use, health care, higher education, immigration, intellectual property, labor and employment, real estate, and trusts and estates law. The firm and its attorneys are consistently recognized by the industry's leading law firm and attorney ranking programs, including Chambers and Partners, Best Law Firms® and The Best Lawyers in America®.

hc1 + Accumen, together, unlock the vast potential of actionable lab data to transform labs into a strategic asset. Health system executives often face challenges in improving patient care and financial performance. By partnering with hc1 + Accumen, health systems can gain profitable new growth and improve patient outcomes. Our solutions use advanced data management, analytics, and workflow automation powered by AI to uncover actionable insights and hidden risk signals, delivering innovation, operational and clinical excellence, and revenue growth across the entire care continuum. With over a decade of experience and thousands of health systems and labs leveraging our technology and consultative services to care for nearly 100 million patients, we provide the expertise needed to unlock the strategic value of your lab data, improving patient outcomes and boosting financial performance. Healthcare Progress Starts Here.™ With hc1 + Accumen.

HTI accelerates drug discovery for Biotech and Pharma companies by providing structure determination services using cryogenic-electron microscopy (cryo-EM) and machine learning based image processing software. As a member of the Oregon Bioscience Incubator, HTI is partnering with leading research institutions and cryo-EM centers.

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are more than 10,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions.

HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow's footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics. We try to embody the best of both technology and healthcare companies and hire people who are passionate about living our mission to save lives, improve the patient experience and reduce the overall cost of care. For more information, visit www.heartflow.com.

Vista.ai is harnessing the power of artificial intelligence (AI) to offer clinicians an easy, cost-effective and stress-free way to conduct MRI studies. The company's FDA 510(k) cleared MRI CoPilot™ software-only solution automates and dramatically simplifies a CMR exam, enabling any MRI tech to perform a CMR in a standard mixed-use scanner time slot. Available for use on Siemens Healthineers and GE Healthcare MRI scanners, MRI CoPilot™ • Eliminates the need for specialized CMR technologist • Allows CMRs to fit into your mixed-use scanner standard time slot • Makes scans less stressful for the technologist • Gives patients greater comfort and convenience Vista.ai is funded by Khosla Ventures, and the National Institute of Health's Small Business Innovation Research program.

Heinrich Heine University Düsseldorf is a Higher Education institution that offers a wide range of academic programs and research opportunities.

HelixNano is building the world's most advanced mRNA platform to enable previously impossible applications across human and non-human biology

Hengrui Therapeutics, Inc. (HTI), located in Princeton, NJ, is a biotech focused on early-stage clinical development of innovative therapeutics in areas of major unmet medical needs, such as oncology, metabolic and autoimmune disorders.

Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. Additionally, CRV431 shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. The multiple mechanisms of action of CRV431 equate to many therapeutic opportunities for alleviating the life-threatening risks of liver disease. CRV431 has been tested in Phase 1 human clinical trials. Our drug candidate demonstrated good safety and tolerability in oral doses ranging from 75 mg to 525 mg. As expected, the pharmacokinetics of CRV431 showed increasing maximal blood concentrations as doses increased. Systemic blood exposures demonstrated good linearity up to 375 mg, which we anticipate will be more than sufficient for efficacy, based on our preclinical testing. The half-life of CRV431 was long and supports once daily oral administration. Data from our preclinical program and our phase 1 clinical trial support the further advancement of CRV431 in liver disease.

Imagine your drug’s effect lasting for months, after one single dose, and with fewer side effects—Hera Health Solutions is turning this vision into reality. Pharma companies can rapidly turn their promising APIs into long-acting, precise, and profitable therapeutics. How? Through our proprietary, cutting-edge nanotechnology-based drug delivery platform. The best part? The platform is: ♻️ Biodegradable: Resorbs into the body. 💊 Versatile: Delivers your API through implants, pellets, patches, and more. ⏳ Long-acting: Lasting up to 48 months! We are focused on significant healthcare and industry challenges. Our mission is to revolutionize drug delivery and transform patient care. 💭 Send the direct message “Long-acting” to Hera’s LinkedIn inbox to explore your API’s potential. Or visit: https://www.herahealthsolutions.com/contact

Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For more information, please visit www.hifibio.com.

Aktiia, now trading under Hilo, was established in 2018 to transform how blood pressure is measured and therefore managed. Hilo is transforming blood pressure monitoring with cuffless, AI-powered technology that delivers continuous, accessible insights for individuals and healthcare professionals. Our foundation model is trained on billions of optical signals and hundreds of millions of readings from over 120,000 users—one of the largest datasets in the field. Backed by a multidisciplinary team with deep expertise in biomedical signal processing, Hilo has contributed to over 120 peer-reviewed publications and holds more than 35 patents. Headquartered in Switzerland, we’re expanding globally to redefine how blood pressure is measured and managed.

Hippocratic AI’s mission is to develop the first safety-focused Large Language Model (LLM) for healthcare. The company believes that a safe LLM can dramatically improve healthcare accessibility and health outcomes in the world by bringing deep healthcare expertise to every human. No other technology has the potential to have this level of global impact on health. The company was co-founded by CEO Munjal Shah, alongside a group of physicians, hospital administrators, healthcare professionals, and artificial intelligence researchers from El Camino Health, Johns Hopkins, Washington University in St. Louis, Stanford, Google, Microsoft, Meta and NVIDIA. Hippocratic AI has received a total of $137 million in funding and is backed by leading investors, including General Catalyst, Andreessen Horowitz, Premji Invest, SV Angel, NVentures (Nvidia Venture Capital), and Greycroft.

HistoIndex is a digital pathology company based in Singapore, founded in 2010. It specializes in AI-driven, stain-free tissue analysis, focusing on disease assessment, particularly for fibrosis and liver-related conditions. The company utilizes its proprietary Second Harmonic Generation (SHG) imaging technology to provide high-resolution visualization of collagen and other structural proteins, enhancing the accuracy of pathology assessments. HistoIndex offers stain-free digital pathology services that detect and quantify fibrosis, inflammation, and other biomarkers in tissues such as the liver, kidney, and skin. Its AI image-analysis platforms support reproducible quantification of morphological features, which is beneficial for clinical trials and diagnostics. The company collaborates with research institutions and pharmaceutical companies to evaluate drug efficacy in various diseases, including metabolic dysfunction-associated liver conditions. With a global presence, HistoIndex operates imaging centers and maintains partnerships across multiple countries, including the US, UK, and India.

We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. This allows us to be a company that prospers, grows and empowers women to experience healthier lives. None of this would be possible without the talent, skills and aspirations of our employees. Their expertise and dedication to developing and sharing more robust, science-based certainty drives our increasingly global presence, as well as a pipeline that responds to the unmet health and wellness needs of women, families and communities. What powers our growth across Breast & Skeletal Health, Diagnostic Solutions, and GYN Surgical Solutions is also what differentiates us: the exceptional and clinically proven ability of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfill by always challenging ourselves to improve health through better technology, education and market access. Our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses. We work toward this goal every day, always aware that in an increasingly complex and competitive global environment, we must continually earn the trust of our customers and their patients. By focusing on women’s health while still delivering health benefits to everyone, we are setting a new standard of excellence that is strengthened by purpose, driven by passion and brought to life by our promise of more certain early detection and better health outcomes. To view our community guidelines, visit: www.hologic.com/social-media

Honeywell is a Fortune 500 company that invents and manufactures technologies to address tough challenges linked to global macrotrends such as safety, security, and energy. With approximately 110,000 employees worldwide, including more than 19,000 engineers and scientists, we have an unrelenting focus on quality, delivery, value, and technology in everything we make and do. For additional information on how Honeywell processes your personal information please visit https://www.honeywell.com/privacy-statement.

The Future of Microsurgery is Robotics and AI. Horizon Surgical Systems, founded in 2021 by experts in ophthalmology and medical robotics, is at the forefront of innovation in microsurgery. Our groundbreaking product, Polaris, leverages state-of-the-art robotics, advanced medical imaging, and AI to extend the capabilities of surgeons beyond their current limitations. With a foundation rooted in academic excellence and a vision for the future, Horizon is committed to revolutionize global healthcare through technological innovation, bringing a new era of precision, enhanced outcomes, and safety to eye care.

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.

HT BioImaging is a medical imaging company based in Tel Aviv, Israel, founded in 2015. The company specializes in innovative imaging technologies aimed at early cancer detection. Its main product is a patented medical imaging platform that uses Heat Diffusion Imaging (HDI) technology to create real-time images from heat diffusion in tissues. This platform is designed for immediate cancer detection at the point of care and in operating rooms. In addition to its primary focus on human healthcare, HT BioImaging has a subsidiary called HTVet, which applies its technology to the veterinary market. HTVet offers HT Vista, a non-invasive medical device that helps veterinarians rule out cancer in pets during clinical visits. The company serves hospitals and clinics, particularly in oncology and surgery, and is supported by a team of experts in various fields, including AI and thermodynamics.

Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders. In order to meet the highest international standards, Hua Medince developed a powerful internal research quality supervision system Q (QC/QA) based on the advanced open innovation model VIC (VC + IP + CRO).

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. Sign up for our updates here: https://bit.ly/HMBDNews

Hummingbird extracts deep insights into disease through the integrated analysis of both disease and immune system derived small RNA biomarkers from whole blood. This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases.

The Swoop® system brings MR brain imaging within reach. Our mission is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that has redefined brain imaging with the Swoop® system—the world's first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020. It is a portable ultra-low field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing.

At iCAD, we believe that is possible to create a world where cancer can't hide. Leveraging the power of artificial intellegence (AI), we empower healthcare providers to more accurately, reliably, and quickly detect disease and improve outcomes. The ProFound Breast Health Suite offers a comprehensive portfolio of clinically proven AI technologies for breast cancer detection, automated breast density assessment, and short-term personalized risk evaluation providing certainty and peace of mind - Optimizing every patient's opportunity to live better, longer lives! To learn more, visit www.icadmed.com.

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

Welcome to the cutting edge of spatial biology and translational research! We're a specialized Contract Research Organization (CRO) and a CLIA High Complexity-certified, CAP-accredited clinical diagnostic laboratory, dedicated to empowering your scientific pursuits! Our focus lies in the field of spatial biology, spatial phenotyping, tumor micro-environment mapping, multiplex immunofluorescence (mIF), IHC, histology, digital pathology, digital and quantitative PCR (dPCR and qPCR), as well as next-generation sequencing (NGS). We use cutting-edge equipment to provide next-generation tissue pathology services, including high-resolution imaging and comprehensive analysis of tissue samples. Our collaborators include scientific teams across the drug development pipeline. Whether you're trying to identify predictive biomarkers or stratify patients, we can help you study the intricate interplay between cells and their surroundings, unlock insights into disease mechanisms, and uncover novel targets. Our team of experts can provide you with end-to-end support including method development and validation, sample testing, regulatory compliance, and clinical trial logistics.

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

IFOWONCO uses advanced computational modelling techniques coupled with state of the art machine learning to rapidly identify and optimize drug candidates.

More than half of all clinical trials fail due to safety issues. Discovering drugs that show therapeutic potential is difficult, time-consuming, and expensive. But of those found, it is harder still to find those drugs which do not also have severe side effects and can pass through clinical trials. Most of these drugs are shelved and never reach patients. Safety issues are tough to fix without weakening the therapeutic effect, involving a mix of chemistry, biology, and knowledge of how humans will respond. Our proprietary AI model, SAFEPATH©, applies deep learning to our combined bioinformatics and cheminformatics datasets to solve drug safety issues. SAFEPATH© utilises the latest deep learning approaches to identify the mechanism of toxicity, predict its effects on the human body, and balance that with therapeutic effectiveness. We are building at speed a robust pipeline of matured assets. We look at historically failed clinical trials to identify the most promising targets as well as internal projects that were abandoned. By focusing on safety problems that occur in Preclinical, Phase 1, or Phase 2 trials, we are able to identify the most promising drugs therapeutically, turn them around quickly, and get them to patients faster than starting drug discovery from scratch. Our mission is to bring more treatments to patients, faster. Thousands of life-changing drugs fall at the last hurdle and never reach patients. We’re here to change that.

Ikonopedia is a next-generation breast radiology reporting and patient tracking system. Our closed-loop system is automated to track and monitor patients to full resolution of all clinical concerns. Clinical reports are clear, consistent, and 100% compliant with the ACR BI-RADS® Atlas 5th Edition. Ikonopedia is MQSA-compliant and offers screening and diagnostic modalities that will improve patient safety and save valuable time for the radiologist and staff.

We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization. Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity. Please visit our webpage to know more about our products and offerings https://iktos.ai/products/

AI-powered fertility care

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

Immune IQ has developed, in collaboration with Honeywell, the Immune Reveal platform. It reads disease information from a patient's immune system in 5 minutes to rapidly identify critical diseases, many not detectable today. Our powerful diagnostic approach has a much lower cost-per-test, a greater range of disease identification, and a shorter time to results than other cellular- and mRNA-based approaches. Immune IQ's initial focus is sepsis, one of the world's greatest healthcare challenges.

ImmunoMind is a UC Berkeley SkyDeck alumnus company, focused on understanding drug-human interactions to create more effective immunotherapies for underserved populations.

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry's most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome. 1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035​; p.118

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.

IMU Biosciences is a UK-based techbio company that is revolutionizing immune powered precision medicine by mapping the immune system in unprecedented detail and scale. Their CytAtlas platform combines systems-level immunophenotyping with an AI platform to gain a new understanding of the immune system across health and disease.

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Extract systems scale information from complex disease biology, identify and detect disease specific molecular biomarkers, signatures at prodromal or pre-symptomatic stages. We believe most diseases can be detected early, enabling early personalized therapeutic intervention to preempt full development of diseases, ushering in preemptive medicine.

Inari is the SEEDesign™ company, using new breeding technology to push the boundaries of what is possible by designing nature-positive seeds for a more sustainable global food system. A combination of AI-powered predictive design and a pioneered multiplex gene editing toolbox enables us to unlock the full potential of seed and advance critical solutions with broad applications for growing more food with fewer resources.

By combining machine learning with advanced chemistry, inBiome enables microbiology labs over the world to rapidly and easily identify bacteria in a wide range of clinical sample types, including complex microbiota. Even uncultivable- and antibiotics treated species are detected. Current applications include replacing traditional culture in ICU’s for more accurate, same day results, infection control, gut flora analysis and various r&d applications for healthcare, pharmacy and food industies. Promising new applications currently undergoing clinical trials include IBD and Sepsis dagnostics and preventive screening.

Biological Software is one or more synthetic molecules that execute complex functions, specified from a program, in a biological system. We are creating tools to develop increasingly powerful biological software for the rational design of novel, broadly accessible medicines and biotechnologies previously out of reach. Our antedisciplinary team of scientists, machine learning researchers, engineers and entrepreneurs is growing. If you are excited to learn, teach, discover, and create together in pursuit of learning life's languages to improve the lives of billions of people around the world, please visit our website.

Indiana University is a Higher Education institution that provides academic programs and conducts research.

Indica Labs is a digital pathology company that specializes in advanced software solutions for medical imaging and analysis in the field of healthcare technology.

Inductive Bio is a biotechnology company based in San Francisco, California, founded in 2022. The company specializes in using advanced machine learning and data analytics to enhance the compound optimization process in small molecule drug discovery. With a seed funding of $4.3 million, Inductive Bio aims to address challenges in Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) during drug development. The company's core offering is a proprietary dataset combined with sophisticated machine learning models. This platform enables scientists to efficiently optimize initial compounds into viable leads and development candidates, providing real-time predictions and insights throughout the drug design process. Inductive Bio collaborates with pharmaceutical companies, biotech firms, and research institutions, including a partnership with Nested Therapeutics focused on precision medicine for challenging cancers.

InduPro is a biotechnology company that brings proteins on the cell surface closer together, manipulating their interactions and opening new possibilities for treating various conditions.

IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest block-chain encrypted repository of indigenous and diasporic African clinical and multi-omics data for disease prevention/detection, drug discovery and development, clinical disease management, and precision health equity.

Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, developing vaccines for the treatment of cancer.

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions. *Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

InfoBionic.Ai's MoMe® ARC system empowers physicians with control to transform the efficiency with which they manage cardiac arrhythmia detection and monitoring processes for their patients. Leveraging a comprehensive, Cloud-based remote patient monitoring platform – the first and only of its kind – we deliver on-demand, actionable monitoring data and analytics directly to the physicians themselves. The MoMe® Kardia 3-in-1 device streams continuous ECG, respiration, and motion data to the Cloud for analysis, and delivers automated reporting to an iPad and or a web-based portal where physicians can access and interact with the data they need, in the detail they want – anytime, anywhere.

Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer's, Parkinson's or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.

Innophore is a biotechnology company based in Graz, Austria, founded in 2017. It specializes in drug and enzyme discovery, primarily serving the biotech and pharmaceutical industries. As a spin-off of acib GmbH and the University of Graz, Innophore is supported by strategic investor EOSS Industries GmbH. The company focuses on developing high-value industrial and therapeutic enzymes, as well as environmentally friendly chemical production processes. Innophore employs an AI-guided platform that utilizes advanced 3D point-cloud technology to analyze protein structures, enhancing the identification and optimization of protein candidates. Its Catalophore platform improves traditional methods, enabling more effective drug repurposing and side-effect prediction. With access to high-performance supercomputing resources, Innophore can analyze extensive protein structure databases, accelerating research and development in the biotech sector. The company collaborates with a diverse team of experts and has established partnerships with leading global companies, including Merck and Henkel.

Climate change is the challenge of our generation. As innovators, we believe disruptive technology can bring performant solutions to the most dire challenges we face as a society. As we seek a more respectful way of living on our planet, nature itself has much to offer and teach us, starting with feeding the world of tomorrow with better nutrients - for animals, people and our planet - through insects. At Innovafeed, we are committed to inventing efficient technologies that reproduce Nature's processes on a large scale. By building a circular and zero waste agri-food chain replicating insect's role in nature, we want to reinvent our way of living with higher quality, sustainability and resilience, for everyone. We are a team of pragmatic dreamers who believe performance and positive impact can go hand in hand to reshape the world we leave to future generations.

INNOVIMMUNE is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune, Inflammatory and Oncologic Diseases. Follow us on Twitter: @Innovimmune

Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding.

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

Buys life science software companies.

Insight Medbotics is developing MRI-guided robotics to bring together the insights only MRI can provide with the minimally invasive access and precision of robotics. Our MRI-compatible robot, IGAR, has been clinically demonstrated. As the only company to receive a FDA 510(k) clearance for use of a robot inside an MRI, Insight Medbotics is now advancing the technology to improve the standard of care for prostate cancer. Our vision is to bring our advanced MRI-guided robotic technology to procedures where accuracy and precision matter most to patients, physicians and hospitals.

InsightRX empowers life science and provider healthcare organizations to individualize treatment from clinical development to the point of care.

Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

We combine synthetic biology and machine learning to control cellular stress responses for next-generation therapeutics.

Integro Theranostics is a clinical stage company developing fluorescent imaging agents and associated medical devices that enable surgeons to readily see and remove cancerous tissue. This accurate, real-time visualization of cancer tissue facilitates a more complete removal of cancer during surgery. Integro Theranostics was born out of a collaboration between Kingdom Capital (values based private investment company) and Washington University School of Medicine. We are combining the clinical infrastructure of a top research medical center, the technology of a world renowned scientist, and the resources of Kingdom Capital to commercialize this transformative technology and improve surgical outcomes for cancer patients.

Improving healthcare through innovative technology is at the core of Intelerad’s work. Our scalable medical imaging platform connects clinicians to a powerful imaging ecosystem that is fast, smart and tapped into the data they need, no matter their location. We’re focused on delivering a best-in-class medical image management solution that improves provider efficiency, decreases the cost of healthcare, and improves the overall health of populations. For more information, visit www.intelerad.com. L'amélioration des soins de santé grâce à des technologies innovantes est au cœur du travail d’Intelerad. Notre plateforme d'imagerie médicale évolutive connecte les cliniciens à un écosystème d’images puissant, rapide et intelligent qui exploite les données dont ils ont besoin, peu importe leur emplacement. Nous concentrons nos efforts pour offrir la meilleure solution de gestion d'images médicales de l’industrie, qui augmente l'efficacité des fournisseurs, qui réduit le coût des soins de santé et qui améliore la santé globale des populations. Pour plus d'information, visitez www.intelerad.com/fr.

Inteliquet, an IQVIA business, Inteliquet is a leading provider of innovative technology and comprehensive support services for cancer clinical researchers. We bridge sponsors, patients and cancer centers nationwide for the ultimate purpose of increasing patient access to cancer trial treatment options. From trial selection to patient matching, Inteliquet enables a streamlined and more accurate journey to patient enrollment. To learn more about Inteliquet, visit https://inteliquet.com/

InterAx Biotech integrates experimental and computational pharmacology to reveal critical properties of novel GPCR drug candidates. The company is specialized in GPCR drug discovery and covers hit-generation, hit-to-lead and lead optimization for all targets including orphan. InterAx Biotech is a Swiss drug discovery company that focuses on developing drugs targeting disease-specific GPCR heterodimers. The company is pioneering computational pharmacology for drug discovery and has entered into R&D agreements with other organizations for drug development. InterAx Biotech also announced the appointment of seasoned pharmaceutical executive, Mark Levick, MD, Ph.D., as a new board director.

InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease. We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

We are a Swiss-based early-clinical stage biotech start-up. Using our breakthrough technology, ACINDA, we develop first-in-class, protein-protein interaction antagonists against invasive cancers.  Invasight's precise therapies will make a positive difference in the lives of patients with invasive cancers. 

InveniAI is pioneering AI and machine learning to map and identify breakthrough innovation across industries. Our platform, AlphaMeld, is an Artificial Intelligence (AI) based system that monitors millions of data points every day to identify signals for breakthrough events and provides a first mover advantage in detecting early signals of innovation. It combines human ingenuity and experience, with ceaseless, comprehensive and efficient machine learning that ensures no data point is missed in the pursuit of Alpha signals. AlphaMeld monitors developments daily across industries and rank orders them on their breakthrough potential. Visit www.inveniai.com for more details. Connect with us on Twitter: @Inveni_AI Careers: We are always on the lookout for talent to join our team at our US headquarters in Guilford, CT USA. We are not hiring at present. Please check back or contact us at +1 203 643 8002. Important Note on Our Hiring Process at InveniAI (inveniai) At InveniAI, we are committed to upholding the highest standards of transparency and integrity in everything we do. As part of our dedication to providing a fair and genuine hiring process, we would like to address a crucial matter. It has come to our attention that some individuals may be receiving fraudulent claims requesting money or personal information under the guise of being associated with InveniAI's hiring process. These unauthorized and fraudulent individuals are sending emails from domain names which are similar to our official domain name ‘inveniai.com’. When the recipient clicks on the domain name provided by the fraudulent individuals, they may be redirected to our website (www.inveniai.com). All individuals are requested not to communicate with any email id other than our official email id(s) that end with ‘@inveniai.com’. We want to make it clear that this is not how we operate, and we take this matter very seriously. Our Policy: No Course Registration: We want to emphasize that

Invenio Imaging is a medical device start-up based in Santa Clara, CA dedicated to advancing the care of cancer patients by combining intraoperative histologic imaging with artificial intelligence. Our technology, the NIO® Laser Imaging System has been used in over 2500 cancer treatment procedures at major cancer centers both in the US and in Europe. In 2021 Invenio received a Medical Design Excellence Award, was selected to be a Rosenman Innovator and received CE Mark to commercialize in Europe.

InvenireX is a biotechnology company developing real-time, ultra-sensitive Nucleic-acid detection instrumentation powered by the latest AI neural networks.

Invicro is a company in the medical imaging and biotechnology industry that specializes in imaging services for pharmaceutical and life sciences companies.

INVI MindHealth was founded at the University of Oxford and leverages learnings from the Health Pillar of The SEAL Future Foundation, a 501(c)3 co-founded by Jonathan. INVI combines the power of biometrics, deep learning analytics, and human networks to provide personalized mental health support.

InVirtuoLabs is a new-generation laboratory for drug discovery. We design novel drugs by combining advanced machine learning techniques with physics-based simulations to rapidly identify and optimize promising drug candidates.

Invitrocue Limited is a biotechnology company based in Singapore, founded in 2012. The company specializes in advanced 3D cell-based models and personalized oncology solutions, operating globally with a presence in Australia, China, Hong Kong, and Germany. Invitrocue offers a range of services, including the Onco Patient-Derived Organoid (PDO) Test, which uses patient-derived tumor cells to tailor cancer treatments. Their 3D CelluSponge Technology provides a scaffold-based system for drug metabolism studies, toxicology assessments, and infectious disease modeling. Additionally, they offer customized services for disease modeling and assays, focusing on respiratory diseases and liver infections, as well as digital pathology and medical imaging to support drug testing and organoid analysis. The company collaborates with industry networks to develop preclinical models, enhancing drug discovery and therapeutic outcomes.

ioGenetics

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry's most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome. 1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035​; p.118

IQVIA applies data science to the continuous advancement of human science to make health care decisions more precise, relevant, and even creative.

iRhythm Technologies, Inc. is a digital healthcare company focused on cardiac arrhythmia detection and management using AI-driven wearable technology. The company combines wearable biosensors, cloud-based analytics, and proprietary AI algorithms to analyze heart rhythm data, having served over 8 million patients and analyzed more than 1.5 billion hours of heartbeat data. The flagship product, Zio by iRhythm, is a comprehensive cardiac monitoring platform that includes discreet, long-term ECG monitors and cloud-based analytics that produce clinically actionable reports. iRhythm also offers end-to-end monitoring services for healthcare providers, streamlining the arrhythmia detection process. The company targets cardiologists and primary care physicians, as well as patients needing long-term cardiac monitoring, particularly those at risk of undiagnosed arrhythmias. Under the leadership of CEO Quentin Blackford, iRhythm aims to enhance patient care and reduce healthcare costs through early detection and personalized solutions.

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company's first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company's consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.

Isogenica is a bespoke biotech CRO specialised in solving antibody discovery and engineering challenges with small-format antibodies, particularly VHH single-domains. Sometimes known as nanobodies, sdAbs, or heavy-chain single domains, VHHs offer exceptional robustness, flexibility, and manufacturability - , accelerating antibody discovery and development. Their versatility makes them suitable for use in bi-specifics, ADCs, cell and gene therapies, targeted protein degraders, diagnostics and much more. We believe VHHs are the future of medicine - and our synthetic technology gives our VHH libraries the edge in accelerating your drug discovery and development programmes so you can focus on developing the ideas and technologies that could change lives. Offering the largest and most diverse synthetic VHH (nanobody) libraries available on the market, combined with our proprietary CIS display technology, means that VHH discovery with at Isogenica can interrogate up to 1000x more VHH antibody sequences than other display technologies. Our knowledge and experience of VHH, combined with our synthetic libraries’ size and diversity help deliver better antibodies faster, with higher affinity and broader IP coverage. Our in-house experts tailor each project to meet bespoke needs, allowing us to provide industry-disrupting antibody solutions to our partners in around half the time of a traditional animal immunisation campaign. Originally founded near Cambridge, UK over 25 years ago, Isogenica has evolved to become The VHH Company. As an established and trusted antibody partner, our track record of success includes dozens of lead panels including three clinical-stage assets. This bespoke and collaborative approach to antibody discovery extends to how we do business - working flexibly with different partners with uncompromising passion and dedication.

Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we're working at the cutting edge in the new era of ‘digital biology'. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.

The iSono Health has developed the world’s first AI-driven platform with an automated, portable, and wearable ultrasound to empower women and their physicians with early breast cancer detection and monitoring. Our patented compact ultrasound scanner captures 3D images by automatically scanning the whole breast volume in 2 minutes. The device connects to a smartphone/tablet/laptop. The data is transferred to a secure cloud for image processing and storage. Our machine-learning algorithm uses acoustic biomarkers to identify abnormal masses. Our platform’s automated operation and software expand ultrasound use in point-of-care diagnostics and monitoring of breast health at radiology centers, walk-in, and mobile clinics. iSono Health offers women and healthcare providers : Safety: No Radiation Actionable Feedback with AI Fast: 2min Scan Easy to Use

Isospec Analytics is a life science company that aims at simplifying molecular identification. They provide high detection sensitivity suitable for bioanalytical applications and offer next-level molecular intelligence to empower biotechnology. Their technology takes the guesswork out of biomolecular analysis and they have raised $1.9m for their breakthrough biomolecular analysis technology.

IUPUI is a Higher Education institution that offers a wide range of academic programs and research opportunities.

We are on a mission to create the next century’s worth of impact on human health, starting with early detection. Since our founding in 2018, we have been operating at the convergence of artificial intelligence, transcriptomics and liquid biopsy — applying the most advanced compute to the most fundamental language of the human cell to create the world’s most advanced early detection blood tests. Our disease-agnostic platform is revolutionizing healthcare diagnostics, providing a reliable and scalable approach to solving real-world problems for pandemic diseases, from oncology to metabolic health. To date, our brain trust of visionary entrepreneurs and world-class scientists and technologists have conceived, created and scaled three pioneering early detection companies — @mammogen, @liquidlung & @hepgene — leveraging our novel end-to-end AI-powered platform to usher in a new era of clinical assays capable of detecting early-stage disease with unprecedented accuracy, affordability and accessibility. To learn more about us visit IVBH.studio or send us a note at info@IVBH.studio.

We, at iVis Technologies, are considered as the pioneers and innovative thinkers in corneal eye surgery since 1996, the year we launched CIPTA®, our dedicated software for corneal surgery customization, while the majority of refractive surgeries were executed as standard ablations worldwide. Since then, we also considered low invasiveness treatments and patients' wellbeing as the fundamental driving concepts in our R&D activities and thus we developed cTen™, our exclusive no-touch one-step procedure for refractive and therapeutic corneal surgery as the ultimate alternative to LASIK and patient's safety. Nowadays, we are offering the 4D iVis Suite™. the most advanced corneal surgery platform, which includes a comprehensive refractive products portfolio of medical devices. Our iVis Suite™ gives Surgeons the ultimate capability to execute customized refractive treatments correcting wide range of corneal refractive errors with outstanding clinical results and with the lowest possible invasiveness. iVis' R&D activities, along with our mindset for continuous innovation, are the core of our care. Core is Care. Recently, we have introduced the second generation of Precisio™, the world's most advanced High Resolution Tomographer, able to detect the whole anterior corneal segment, incorporating highly detailed epithelial maps and uniquely using a voice driven full automated exam acquisition, for corneal pathology diagnosis and corneal surgery.

Advancing medicine and human health by transforming data into clinically meaningful insights. IXICO is a premier neuroimaging provider helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights. Bringing together world-class therapeutic expertise, breakthrough analytics and operational excellence, IXICO is the proven partner of choice for imaging biomarker solutions in CNS clinical trials.

JADBio’s purpose-built AutoML platform provides leading-edge AI tools and automation capabilities enabling life-science professionals to build and deploy accurate and interpretable predictive models with speed and ease, even if they have no data science expertise. For life-science professionals, knowledge discovery is fundamental and sets the requirements apart when it comes to data analysis. JADBio can analyze small sample sizes or very large feature sets, focusing on feature selection and interpretation of the predictive model.

Jan Medical is a medical device start-up company dedicated to providing physicians critical data for accelerating and expanding therapy while improving the diagnostic experience for patients with brain disorders. Its proprietary platform technology, BrainPulse, uses accelerometers on a non-invasive headset to detect skull motion resulting from pulsatile blood flow into the brain. The BrainPulse system is an FDA cleared device for cranial motion measurement currently under research for a variety of neurological conditions. Jan Medical has developed clinical experience and collected valuable clinical data with the BrainPulse device in a variety of indications such as concussion, stroke, aneurysm, AVM, and vasospasm detection. Visit us at www.janmedical.com to better understand our company, our technology and our people.

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

Javelin Biotech makes predictive drug discovery platforms that merge human biology with computational biology to improve the speed and predictive power of preclinical testing. The Javelin platform combines human tissue chips, also known as organs-on-chip, with translational software to provide predictive solutions for drug discovery.

At JaxBio, we are revolutionising the way cancer is diagnosed and managed by making cancer detection simpler, quicker, and more precise, and we're doing that through our innovative blood test technology. Our unique blood test offers advantages over traditional methods and traditional liquid biopsies. Based on its high sensitivity together with low cost and simplicity, we can deliver results faster with improved accuracy. By improving screening and early detection capabilities for cancer, healthcare providers and patients can now make better informed decisions sooner when time is of the essence. We use novel artificial intelligence (AI) algorithms to identify sets of biomarkers that are effective in detecting various types and subtypes of cancer at different stages. Our tests aren't just for initial diagnosis; they're also valuable tools for monitoring disease status and predicting how well a patient will respond to therapy. Our platform technology can also be used in a range of diseases, including various types of cancer, neurodegenerative diseases, and heart diseases. Connect with us to learn more.

JD Bioscience (JDB) possesses the core technology and experience to design small molecules for the treatment for a variety of diseases. With its ability and expertise, JBD is developing new drug candidates for metabolic-related diseases.

Jeeva Clinical Trials Inc. specializes in decentralized clinical trial solutions, offering a unified SaaS platform that enhances global patient engagement and streamlines trial operations. The company utilizes AI-powered tools and modular technology to support efficient trial management, allowing sponsors and medical centers to conduct studies under a single login. Their services include decentralized and hybrid trial solutions, patient recruitment and retention tools, and comprehensive clinical data management. Jeeva's platform features a next-generation Clinical Trial Management System (CTMS) for real-time oversight and protocol adjustments. The company prioritizes security and compliance, adhering to HIPAA, GDPR, and other regulatory standards. Jeeva has successfully implemented its solutions in oncology trials, achieving significant improvements in patient enrollment and data accuracy. They also support academic research, reducing costs and administrative burdens for campus-based studies. With a focus on scalability and workflow standardization, Jeeva provides a patient-centric approach to modern clinical trials.

JOGO Health uses wearable sensors and AI to treat chronic pain, migraine, post-stroke, and pelvic floor disorders using the foundational science of digital therapeutics.

Johns Hopkins University is a higher education institution known for its research initiatives and academic programs.

✨ Journey Biosciences is on a mission to shift the future of care. 🧬 Our flagship solution blends the precision of NaviDKD®, a clinically-validated predictive screening, with the AI-driven insights of Compass™, to offer up to 12 years of advanced diabetes-related kidney disease (DKD) detection, plus tailored intervention strategies to slow or prevent progression. 🎯 This approach improves patient outcomes, optimizes resource allocation, and reduces costs. 🔍 Discover more about our transformative approach at journeybio.life.

JuneBrain is an early start-up company based in the Washington, DC area. Our mission is to develop a telehealth eye-scanning system that allows clinicians to monitor patients with eye and brain disease outside of the traditional clinical setting, leading to earlier detection of new disease and improved monitoring of treatment efficacy. Though our mission begins in the eye care community, our long-term goal is to extend the use of our device into the broader neurological disease population, thus creating a pathway towards more frequent, widely accessible monitoring of eye and brain health.

Junevity is a biotech rewinding complex metabolic disease. Based on 6 years of breakthrough research at UCSF, Junevity's REWIND platform identifies high-level regulators of metabolic disease with known pharmacological pathways. Junevity is advancing multiple therapeutic programs towards a new era of medicines.

Juvena Therapeutics is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions.

Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering. Juvenescence has a broad pipeline in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span.

We are a clinical stage company developing novel therapeutics inspired by kanna, or Sceletium tortuosum. Kanna is a medicinal succulent traditionally used by the San hunter-gatherers of South Africa.

Kailera Therapeutics (Kailera) (previously Hercules CM NewCo) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health.

Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to your lifestyle.

치료 약물이 없는 뇌퇴행성 질환과 암 질환을 타겟으로 한 혁신 신약 개발 전문기업

Kapoose Creek Bio is a Canadian biotech company using AI technologies to uncover small molecule medicines from nature with unprecedented speed and scale. Our R&D efforts are supported by off-grid research facilities in the hunt for undiscovered chemistry in environments of unique biodiversity. We have developed a platform – unEarth Rx – that integrates phenotypic screening with advanced machine and deep learning to accelerate the identification of high-quality drug leads and simultaneously determine their mechanism of action. The result is a comprehensive, data-rich, functional map of nature's chemistry for accelerated discovery and development of new small molecule medicines. We are building a diversified portfolio of stakes in the next generation of critical medicines, focusing our platform on neuroscience, cancer and infectious disease. Currently our development pipeline is concentrated on lead assets with exciting potential in neurological indications.

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.